Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2018 | Apr. 30, 2018 | |
Document and Entity Information | ||
Entity Registrant Name | HCP, INC. | |
Entity Central Index Key | 765,880 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2018 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 469,755,917 | |
Document Fiscal Year Focus | 2,018 | |
Document Fiscal Period Focus | Q1 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Real estate: | ||
Buildings and improvements | $ 11,532,338 | $ 11,239,732 |
Development costs and construction in progress | 344,948 | 447,976 |
Land | 1,808,210 | 1,785,865 |
Accumulated depreciation and amortization | (2,826,325) | (2,741,695) |
Net real estate | 10,859,171 | 10,731,878 |
Net investment in direct financing leases | 713,463 | 714,352 |
Loans receivable, net | 47,012 | 313,326 |
Investments in and advances to unconsolidated joint ventures | 863,775 | 800,840 |
Accounts receivable, net of allowance of $4,516 and $4,425, respectively | 51,468 | 40,733 |
Cash and cash equivalents | 86,021 | 55,306 |
Restricted cash | 31,947 | 26,897 |
Intangible assets, net | 395,298 | 410,082 |
Assets held for sale, net | 436,155 | 417,014 |
Other assets, net | 583,261 | 578,033 |
Total assets | 14,067,571 | 14,088,461 |
LIABILITIES AND EQUITY | ||
Bank line of credit | 1,092,357 | 1,017,076 |
Term loan | 236,878 | 228,288 |
Senior unsecured notes | 6,398,976 | 6,396,451 |
Mortgage debt | 143,524 | 144,486 |
Other debt | 93,856 | 94,165 |
Intangible liabilities, net | 52,576 | 52,579 |
Liabilities of assets held for sale, net | 8,564 | 14,031 |
Accounts payable and accrued liabilities | 391,942 | 401,738 |
Deferred revenue | 167,975 | 144,709 |
Total liabilities | 8,586,648 | 8,493,523 |
Commitments and contingencies | ||
Common stock, $1.00 par value: 750,000,000 shares authorized; 469,725,220 and 469,435,678 shares issued and outstanding, respectively | 469,725 | 469,436 |
Additional paid-in capital | 8,183,166 | 8,226,113 |
Cumulative dividends in excess of earnings | (3,425,293) | (3,370,520) |
Accumulated other comprehensive income (loss) | (21,307) | (24,024) |
Total stockholders' equity | 5,206,291 | 5,301,005 |
Joint venture partners | 97,744 | 117,045 |
Non-managing member unitholders | 176,888 | 176,888 |
Total noncontrolling interests | 274,632 | 293,933 |
Total equity | 5,480,923 | 5,594,938 |
Total liabilities and equity | $ 14,067,571 | $ 14,088,461 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Balance Sheet Parenthetical Disclosures | ||
Accounts receivable, allowance (in dollars) | $ 4,516 | $ 4,425 |
Common stock, par value (in dollars per share) | $ 1 | $ 1 |
Common stock, shares authorized | 750,000,000 | 750,000,000 |
Common stock, shares issued | 469,725,220 | 469,435,678 |
Common stock, shares outstanding | 469,725,220 | 469,435,678 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Revenues: | ||
Rental and related revenues | $ 279,578 | $ 286,218 |
Tenant recoveries | 37,174 | 33,675 |
Resident fees and services | 142,814 | 140,232 |
Income from direct financing leases | 13,266 | 13,712 |
Interest income | 6,365 | 18,331 |
Total revenues | 479,197 | 492,168 |
Costs and expenses: | ||
Interest expense | 75,102 | 86,718 |
Depreciation and amortization | 143,250 | 136,554 |
Operating | 172,552 | 159,081 |
General and administrative | 29,175 | 22,478 |
Transaction costs | 2,195 | 1,057 |
Total costs and expenses | 422,274 | 405,888 |
Other income (expense): | ||
Gain (loss) on sales of real estate, net | 20,815 | 317,258 |
Other income (expense), net | (40,407) | 51,208 |
Total other income (expense), net | (19,592) | 368,466 |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures | 37,331 | 454,746 |
Income tax benefit (expense) | 5,336 | 6,162 |
Equity income (loss) from unconsolidated joint ventures | 570 | 3,269 |
Net income (loss) | 43,237 | 464,177 |
Noncontrolling interests' share in earnings | (3,005) | (3,032) |
Net income (loss) attributable to HCP, Inc. | 40,232 | 461,145 |
Participating securities' share in earnings | (391) | (770) |
Net income (loss) applicable to common shares | $ 39,841 | $ 460,375 |
Earnings per common share: | ||
Earnings per common share, basic (in dollars per share) | $ 0.08 | $ 0.98 |
Earnings per common share, diluted (in dollars per share) | $ 0.08 | $ 0.97 |
Weighted average shares outstanding: | ||
Basic (in shares) | 469,557 | 468,299 |
Diluted (in shares) | 469,695 | 475,173 |
Dividends declared per common share (in dollars per share) | $ 0.37 | $ 0.37 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Statement of Comprehensive Income [Abstract] | ||
Net income (loss) | $ 43,237 | $ 464,177 |
Change in net unrealized gains (losses) on cash flow hedges: | ||
Unrealized gains (losses) | (5,164) | (302) |
Reclassification adjustment realized in net income (loss) | 125 | 213 |
Change in Supplemental Executive Retirement Plan obligation and other | 104 | 83 |
Foreign currency translation adjustment | 7,652 | 990 |
Total other comprehensive income (loss) | 2,717 | 984 |
Total comprehensive income (loss) | 45,954 | 465,161 |
Total comprehensive income (loss) attributable to noncontrolling interests | (3,005) | (3,032) |
Total comprehensive income (loss) attributable to HCP, Inc. | $ 42,949 | $ 462,129 |
CONSOLIDATED STATEMENTS OF EQUI
CONSOLIDATED STATEMENTS OF EQUITY - USD ($) shares in Thousands, $ in Thousands | Total | Common Stock | Additional Paid-In Capital | Cumulative Dividends In Excess Of Earnings | Accumulated Other Comprehensive Income (Loss) | Total Stockholders’ Equity | Total Noncontrolling Interests | |
Balance at Dec. 31, 2016 | $ 5,941,308 | $ 468,081 | $ 8,198,890 | $ (3,089,734) | $ (29,642) | $ 5,547,595 | $ 393,713 | |
Balance (in shares) at Dec. 31, 2016 | 468,081 | |||||||
Increase (Decrease) in Stockholders' Equity | ||||||||
Net income (loss) | 464,177 | 461,145 | 461,145 | 3,032 | ||||
Other comprehensive income (loss) | 984 | 984 | 984 | |||||
Issuance of common stock, net | 3,472 | $ 427 | 3,045 | 3,472 | ||||
Issuance of common stock, net (in shares) | 427 | |||||||
Conversion of DownREIT units to common stock | 0 | $ 54 | 1,494 | 1,548 | (1,548) | |||
Conversion of DownREIT units (in shares) | 54 | |||||||
Repurchase of common stock | (3,532) | $ (116) | (3,416) | (3,532) | ||||
Repurchase of common stock (in shares) | (116) | |||||||
Amortization of deferred compensation | 3,765 | 3,765 | 3,765 | |||||
Common dividends | (173,629) | (173,629) | (173,629) | |||||
Distributions to noncontrolling interest | (5,659) | (5,659) | ||||||
Issuances of noncontrolling interest | 650 | 650 | ||||||
Deconsolidation of noncontrolling interest | (58,061) | (58,061) | ||||||
Balance at Mar. 31, 2017 | 6,173,475 | $ 468,446 | 8,203,778 | (2,802,218) | (28,658) | 5,841,348 | 332,127 | |
Balance (in shares) at Mar. 31, 2017 | 468,446 | |||||||
Increase (Decrease) in Stockholders' Equity | ||||||||
Cumulative effect of new accounting principle | [1] | 79,144 | 79,144 | 79,144 | ||||
Adjusted balance | 5,674,082 | $ 469,436 | 8,226,113 | (3,291,376) | (24,024) | 5,380,149 | 293,933 | |
Balance at Dec. 31, 2017 | 5,594,938 | $ 469,436 | 8,226,113 | (3,370,520) | (24,024) | 5,301,005 | 293,933 | |
Balance (in shares) at Dec. 31, 2017 | 469,436 | |||||||
Increase (Decrease) in Stockholders' Equity | ||||||||
Net income (loss) | 43,237 | 40,232 | 40,232 | 3,005 | ||||
Other comprehensive income (loss) | 2,717 | 2,717 | 2,717 | |||||
Issuance of common stock, net | 2,774 | $ 382 | 2,392 | 2,774 | ||||
Issuance of common stock, net (in shares) | 382 | |||||||
Repurchase of common stock | (2,144) | $ (93) | (2,051) | (2,144) | ||||
Repurchase of common stock (in shares) | (93) | |||||||
Amortization of deferred compensation | 5,919 | 5,919 | 5,919 | |||||
Common dividends | (174,149) | (174,149) | (174,149) | |||||
Distributions to noncontrolling interest | (5,077) | (5,077) | ||||||
Issuances of noncontrolling interest | 995 | 995 | ||||||
Purchase of noncontrolling interest | (67,431) | (49,207) | (49,207) | (18,224) | ||||
Balance at Mar. 31, 2018 | $ 5,480,923 | $ 469,725 | $ 8,183,166 | $ (3,425,293) | $ (21,307) | $ 5,206,291 | $ 274,632 | |
Balance (in shares) at Mar. 31, 2018 | 469,725 | |||||||
[1] | On January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) No. 2017-05, Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (“ASU 2017-05”), and recognized the cumulative-effect of adoption to beginning retained earnings. Refer to Note 2 for a detailed impact of adoption. |
CONSOLIDATED STATEMENTS OF EQU7
CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Statement of Stockholders' Equity [Abstract] | ||
Common dividends, per share (in dollars per share) | $ 0.37 | $ 0.37 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Cash flows from operating activities: | ||
Net income (loss) | $ 43,237 | $ 464,177 |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
Depreciation and amortization of real estate, in-place lease and other intangibles: | 143,250 | 136,554 |
Amortization of deferred compensation | 5,919 | 3,765 |
Amortization of deferred financing costs | 3,336 | 3,858 |
Straight-line rents | (10,686) | (5,007) |
Equity loss (income) from unconsolidated joint ventures | (570) | (3,269) |
Distributions of earnings from unconsolidated joint ventures | 5,336 | 7,842 |
Deferred income tax expense (benefit) | (2,394) | (8,130) |
Impairments (recoveries), net | (3,298) | 0 |
Loss (gain) on sales of real estate, net | (20,815) | (317,258) |
Loss (gain) on consolidation, net | 41,017 | 0 |
Loss (gain) on sale of marketable securities | 0 | (50,895) |
Other non-cash items | (2,401) | (660) |
Decrease (increase) in accounts receivable and other assets, net | (18,082) | 1,136 |
Increase (decrease) in accounts payable and accrued liabilities | 12,315 | (38,984) |
Net cash provided by (used in) operating activities | 196,164 | 193,129 |
Cash flows from investing activities: | ||
Acquisitions of real estate | (22,121) | 0 |
Development and redevelopment of real estate | (113,648) | (75,166) |
Leasing costs, tenant improvements, and recurring capital expenditures | (19,246) | (22,693) |
Proceeds from sales of real estate, net | 30,392 | 1,206,256 |
Contributions to unconsolidated joint ventures | (3,688) | (8,109) |
Distributions in excess of earnings from unconsolidated joint ventures | 7,257 | 870 |
Proceeds from the RIDEA II transaction, net | 0 | 462,241 |
Proceeds from sales/principal repayments on debt investments and direct financing leases | 132,429 | 185,364 |
Investments in loans receivable, direct financing leases and other | (647) | (15,000) |
Net cash provided by (used in) investing activities | 10,728 | 1,733,763 |
Cash flows from financing activities: | ||
Borrowings under bank line of credit, net | 240,000 | (375,812) |
Repayments under bank line of credit | (170,000) | (37,032) |
Repayments and repurchase of debt, excluding bank line of credit | (1,172) | (647,427) |
Issuance of common stock and exercise of options | 2,774 | 3,472 |
Repurchase of common stock | (2,144) | (3,532) |
Dividends paid on common stock | (174,149) | (173,629) |
Issuance of noncontrolling interests | 995 | 650 |
Distributions to and purchase of noncontrolling interests | (67,542) | (5,659) |
Net cash provided by (used in) financing activities | (171,238) | (1,238,969) |
Effect of foreign exchanges on cash, cash equivalents and restricted cash | 111 | 7 |
Net increase (decrease) in cash, cash equivalents and restricted cash | 35,765 | 687,930 |
Cash, cash equivalents and restricted cash, beginning of period | 82,203 | 136,990 |
Cash, cash equivalents and restricted cash, end of period | $ 117,968 | $ 824,920 |
Business
Business | 3 Months Ended |
Mar. 31, 2018 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Business | Business Overview HCP, Inc., a Standard & Poor’s (“S&P”) 500 company, is a Maryland corporation that is organized to qualify as a real estate investment trust (“REIT”) which, together with its consolidated entities (collectively, “HCP” or the “Company”), invests primarily in real estate serving the healthcare industry in the United States (“U.S.”). The Company acquires, develops, leases, manages and disposes of healthcare real estate and provides financing to healthcare providers. The Company’s diverse portfolio is comprised of investments in the following reportable healthcare segments: (i) senior housing triple-net; (ii) senior housing operating portfolio (“SHOP”); (iii) life science and (iv) medical office. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2018 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from management’s estimates. The consolidated financial statements include the accounts of HCP, Inc., its wholly-owned subsidiaries, joint ventures (“JVs”) and variable interest entities (“VIEs”) that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations and cash flows have been included. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 . The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”). Recent Accounting Pronouncements Revenue Recognition. Between May 2014 and February 2017, the Financial Accounting Standards Board (“FASB”) issued four ASUs changing the requirements for recognizing and reporting revenue (together, herein referred to as the “Revenue ASUs”): (i) ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), (ii) ASU No. 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”), (iii) ASU No. 2016-12, Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”), and (iv) ASU No. 2017-05, Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (“ASU 2017-05”). ASU 2014-09 provides guidance for revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2016-08 is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2016-12 provides practical expedients and improvements on the previously narrow scope of ASU 2014-09. ASU 2017-05 clarifies the scope of the FASB’s recently established guidance on nonfinancial asset derecognition and aligns the accounting for partial sales of nonfinancial assets and in-substance nonfinancial assets with the guidance in ASU 2014-09. The Company adopted the Revenue ASUs effective January 1, 2018 and utilized a modified retrospective adoption approach, resulting in a cumulative-effect adjustment to equity of $79 million as of January 1, 2018. Under the Revenue ASUs, the Company also elected to utilize a practical expedient which allows the Company to only reassess contracts that were not completed as of the adoption date, rather than all historical contracts. As the primary source of revenue for the Company is generated through leasing arrangements, for which timing and recognition of revenue are excluded from the Revenue ASUs, the impact of the Revenue ASUs, upon and subsequent to adoption, is generally limited to the following: • The Company, along with its JV partners and independent SHOP operators, provide certain ancillary services to SHOP residents that are not contemplated in the lease with each resident (i.e., guest meals, concierge services, pharmacy services, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. The Company records ancillary service revenue within resident fees and services and, under the Revenue ASUs, is required to disclose, on an ongoing basis, ancillary service revenue generated from its RIDEA structures. Included within resident fees and services for the quarters ended March 31, 2018 and 2017 is $10 million of ancillary service revenue. • Prior to the adoption of the Revenue ASUs, the Company recognized a gain on sale of real estate using the full accrual method when collectibility of the sales price was reasonably assured, the Company was not obligated to perform additional activities that may be considered significant, the initial investment from the buyer was sufficient and other profit recognition criteria had been satisfied. The Company deferred all or a portion of a gain on sale of real estate if the requirements for gain recognition were not met at the time of sale. Subsequent to adopting the Revenue ASUs on January 1, 2018, the Company began recognizing a gain on sale of real estate upon transferring control of the asset to the purchaser, which is generally satisfied at the time of sale. In conjunction with its adoption of the Revenue ASUs, the Company reassessed its historical partial sale of real estate transactions to determine which transactions, if any, were not completed contracts (i.e., the transaction did not qualify for sale treatment under previous guidance). The Company concluded that it had one such material transaction, its partial sale of RIDEA II in the first quarter of 2017 (which was not a completed sale under historical guidance as of the Company's adoption date due to a minor obligation related to the interest sold). In accordance with the Revenue ASUs, the Company recorded its retained 40% equity investment at fair value as of the sale date. As a result, the Company recorded an adjustment to equity as of January 1, 2018 (under the modified retrospective transition approach) representing a step-up in the fair value of its equity investment in RIDEA II of $107 million (to a carrying value of $121 million as of January 1, 2018) and a $30 million impairment charge to decrease the carrying value to the expected sales price of the investment (see Note 4). • The Company generally expects that the new guidance will result in certain transactions qualifying as sales of real estate at an earlier date than under historical accounting guidance. The following table illustrates changes in the Company’s consolidated balance sheet as reported and as it would have been reported prior to the adoption of the Revenue ASUs as of March 31, 2018 (in thousands): March 31, 2018 As Reported As Would Have Been Reported Prior to Adoption Investments in and advances to unconsolidated joint ventures 863,775 792,291 Other assets, net 583,261 586,066 Deferred revenue 167,975 178,440 Total stockholders' equity 5,206,291 5,127,147 Additionally, effective January 1, 2018, the Company adopted the following ASUs, each of which did not have a material impact to its consolidated financial position, results of operations, cash flows or disclosures upon adoption: • ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”) and ASU No. 2018-03, Technical Corrections and Improvements to Financial Instruments - Overall (“ASU 2018-03”). The core principle of the amendments in ASU 2016-01 and ASU 2018-03 involves the measurement of equity investments (except those accounted for under the equity method of accounting or those that result in consolidation) at fair value and the recognition of changes in fair value of those investments during each reporting period in net income (loss). As a result, ASU 2016-01 and ASU 2018-03 eliminate the cost method of accounting for equity securities that do not have readily determinable fair values. Pursuant to the new guidance, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. • ASU No. 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”). The amendments in ASU 2016-16 require an entity to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time that the transfer occurs. Historical guidance does not require recognition of tax consequences until the asset is eventually sold to a third party. During the fourth quarter of 2017, the Company adopted ASU No. 2016-18, Restricted Cash (“ASU 2016-18”) and ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”) (collectively, the “Cash Flow ASUs”). ASU 2016-18 requires an entity to reconcile and explain the period-over-period change in total cash, cash equivalents and restricted cash within its statements of cash flows and ASU 2016-15 provides guidance clarifying how certain cash receipts and cash payments should be classified. The full retrospective approach of adoption is required for the Cash Flow ASUs and, accordingly, certain line items in the Company’s consolidated statements of cash flows have been reclassified to conform to the current period presentation. The following table illustrates changes in the Company’s cash flows as reported and as previously reported prior to the adoption of the Cash Flow ASUs during the fourth quarter of 2017 (in thousands): Three Months Ended March 31, 2017 As Reported As Previously Reported Net cash provided by (used in) investing activities $ 1,733,763 $ 1,715,217 Net increase (decrease) in balance (1) 687,930 669,384 Balance - beginning of period (1) 136,990 94,730 Balance - end of period (1) 824,920 764,114 _______________________________________ (1) Amounts in the As Reported column include cash and cash equivalents and restricted cash as required upon the adoption of the Cash Flow ASUs. Amounts in the As Previously Reported column reflect only cash and cash equivalents. In addition to the changes in the consolidated statements of cash flows as a result of the adoption the Cash Flow ASUs, certain amounts within the consolidated statements of cash flows have been reclassified for prior periods to conform to the current period presentation. Such reclassifications primarily combined line items of similar classes of transactions and had no impact on the cash flows from operating, investing and financing activities. Leases. In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the current accounting for leases to: (i) require lessees to put most leases on their balance sheets, but continue recognizing expenses on their income statements in a manner similar to requirements under current accounting guidance, (ii) eliminate current real estate specific lease provisions, and (iii) modify the classification criteria and accounting for sales-type leases for lessors. ASU 2016-02 is effective for fiscal years, and interim periods within, beginning after December 15, 2018. Early adoption is permitted. The transition method required by ASU 2016-02 varies based on the specific amendment being adopted. As a result of adopting ASU 2016-02, the Company: (i) will recognize all of its significant operating leases for which it is the lessee, including corporate office leases, equipment leases, and ground leases, on its consolidated balance sheets, (ii) will capitalize fewer legal costs related to the drafting and execution of its lease agreements, and (iii) may be required to increase its revenue and expense for the amount of real estate taxes and insurance paid by its tenants under triple-net leases. ASU 2016-02 provides a practical expedient, which the Company plans to elect, that allows an entity to not reassess the following upon adoption (must be elected as a group): (i) whether an expired or existing contract contains a lease arrangement, (ii) lease classification related to expired or existing lease arrangements, or (iii) whether costs incurred on expired or existing leases qualify as initial direct costs. Although not yet finalized, the FASB has also proposed an option for lessors to elect a practical expedient allowing them to not separate lease and nonlease components in a contract for the purpose of revenue recognition and disclosure. This practical expedient is limited to circumstances in which (i) the timing and pattern of transfer are the same for the nonlease component and the related lease component and (ii) the lease component would be classified as an operating lease. If finalized, the Company plans to elect this practical expedient as well. The Company is still evaluating the complete impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial position, results of operations and disclosures. Credit Losses. In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments held by financial institutions and other organizations. The amendments in ASU 2016-13 eliminate the “probable” initial threshold for recognition of credit losses in current accounting guidance and, instead, reflect an entity’s current estimate of all expected credit losses over the life of the financial instrument. Previously, when credit losses were measured under current accounting guidance, an entity generally only considered past events and current conditions in measuring the incurred loss. The amendments in ASU 2016-13 broaden the information that an entity must consider in developing its expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. ASU 2016-13 is effective for fiscal years, and interim periods within, beginning after December 15, 2019. Early adoption is permitted for fiscal years, and interim periods within, beginning after December 15, 2018. A reporting entity is required to apply the amendments in ASU 2016-13 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Upon adoption of ASU 2016-13, the Company is required to reassess its financing receivables, including direct financing leases (“DFLs”) and loans receivable, and expects that application of ASU 2016-13 may result in the Company recognizing credit losses at an earlier date than would otherwise be recognized under current accounting guidance. The Company is evaluating the impact of the adoption of ASU 2016-13 on January 1, 2020 to its consolidated financial position and results of operations. The following ASU has been issued, but not adopted, and the Company does not expect a material impact to its consolidated financial position, results of operations, cash flows, or disclosures upon adoption: • ASU No. 2017-12, Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”). ASU 2017-12 is effective for fiscal years, including interim periods within, beginning after December 15, 2018 and early adoption is permitted. The amendments in ASU 2017-12 expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. For cash flow and net investment hedges existing at the date of adoption, a reporting entity must apply the amendments in ASU 2017-12 using the modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. The presentation and disclosure amendments in ASU 2017-12 must be applied using a prospective approach. |
Master Transactions and Coopera
Master Transactions and Cooperation Agreement with Brookdale | 3 Months Ended |
Mar. 31, 2018 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Master Transactions and Cooperation Agreement with Brookdale | Master Transactions and Cooperation Agreement with Brookdale Master Transactions and Cooperation Agreement with Brookdale On November 1, 2017, the Company and Brookdale Senior Living Inc. (“Brookdale”) entered into a Master Transactions and Cooperation Agreement (the “MTCA”) to provide the Company with the ability to significantly reduce its concentration of assets leased to and/or managed by Brookdale (the "Brookdale Transactions"). Through a series of dispositions and transitions of assets currently leased to and/or managed by Brookdale, as contemplated by the MTCA and further described below, the Company’s exposure to Brookdale is expected to be significantly reduced. In connection with the overall transaction pursuant to the MTCA, the Company (through certain of its subsidiaries), and Brookdale (through certain of its subsidiaries) (the “Lessee”) entered into an Amended and Restated Master Lease and Security Agreement (the “Amended Master Lease”), which amended and restated the then-existing triple-net leases between the parties for 78 assets, which account for primarily all of the assets subject to triple-net leases between the Company and the Lessee (before giving effect to the contemplated sale or transition of 34 assets discussed below). Under the Amended Master Lease, the Company has the benefit of a guaranty from Brookdale of the Lessee’s obligations and, upon a change in control, will have various additional protections under the MTCA and the Amended Master Lease including: • A security deposit (which increases if specified leverage thresholds are exceeded); • A termination right if certain financial covenants and a net worth test are not satisfied; • Enhanced reporting requirements and related remedies; and • The right to market for sale the CCRC portfolio (as defined below). Future changes in control of Brookdale are permitted pursuant to the Amended Master Lease, subject to certain conditions, including the purchaser either meeting experience requirements or retaining a majority of Brookdale’s principal officers. The Amended Master Lease preserves the renewal terms and, with certain exceptions, the rents under the previously existing triple-net leases. In addition, the Company and Brookdale agreed to the following: • The Company has the right to sell, or transition to other operators, 32 triple-net assets. If such sale or transition does not occur within one year, the triple-net lease with respect to such assets will convert to a cash flow lease (under which the Company will bear the risks and rewards of operating the assets) with a term of two years, provided that the Company has the right to terminate the cash flow lease at any time during the term without penalty; • The Company has provided an aggregate $5 million annual reduction in rent on three assets, effective January 1, 2018; and • The Company will sell two triple-net assets to Brookdale or its affiliates for $35 million , both of which were sold in April 2018. Also pursuant to the MTCA, the Company and Brookdale agreed to the following: • The Company, which owned 90% of the interests in its RIDEA I and RIDEA III JVs with Brookdale at the time the MTCA was executed, agreed to purchase Brookdale’s 10% noncontrolling interest in each JV for an aggregate purchase price of $95 million . These JVs collectively own and operate 58 independent living, assisted living, memory care and/or skilled nursing facilities (the “RIDEA Facilities”). The Company completed its acquisitions of the RIDEA III noncontrolling interest for $32 million in December 2017 and the RIDEA I noncontrolling interest for $63 million in March 2018; • The Company has the right to sell, or transition to other managers, 36 of the RIDEA Facilities and terminate related management agreements with an affiliate of Brookdale without penalty. If the related management agreements are not terminated within one year, the base management fee ( 5% of gross revenues) increases by 1% of gross revenues per year over the following two years to a maximum of 7% of gross revenues. As of March 31, 2018, the Company had completed the transition of eight SHOP assets; • The Company will sell four of the RIDEA Facilities to Brookdale or its affiliates for $239 million , one of which was sold in January 2018 for $32 million . The remaining three RIDEA Facilities were sold in April 2018 for $207 million ; • A Brookdale affiliate continues to manage the remaining 18 RIDEA Facilities pursuant to amended management agreements, which provide for extended terms on select assets, modified performance hurdles for extensions and incentive fees, and modified termination rights (including stricter performance-based termination rights, a staggered right to terminate seven agreements over a 10 year period beginning in 2021, and a right to terminate at will upon payment of a termination fee, in lieu of sale-related termination rights) and two other existing facilities managed in separate RIDEA structures; and • The Company has the right to sell, to certain permitted transferees, its 49% ownership interest in JVs that own and operate a portfolio of continuing care retirement communities (the “CCRC Portfolio”) and in which Brookdale owns the other 51% interest (the “CCRC JV”), subject to certain conditions and a right of first offer in favor of Brookdale. Brookdale will have a corresponding right to sell its 51% interest in the CCRC JV to certain permitted transferees, subject to certain conditions, a right of first offer and a right to terminate management agreements following such sale of Brookdale’s interest, each in favor of HCP. Following a change in control of Brookdale, the Company will have the right to initiate a sale of the CCRC Portfolio, subject to certain rights of first offer and first refusal in favor of Brookdale. |
Real Estate Transactions
Real Estate Transactions | 3 Months Ended |
Mar. 31, 2018 | |
Real Estate [Abstract] | |
Real Estate Transactions | Real Estate Transactions Dispositions of Real Estate Held for Sale At March 31, 2018 , seven SHOP facilities, two senior housing triple-net facilities and four life science facilities were classified as held for sale, with an aggregate carrying value of $436 million , primarily comprised of real estate assets of $410 million , net of accumulated depreciation of $98 million . At December 31, 2017 , two senior housing triple-net facilities, four life science facilities and six SHOP facilities were classified as held for sale, with an aggregate carrying value of $417 million , primarily comprised of real estate assets of $393 million , net of accumulated depreciation of $93 million . Liabilities of assets held for sale is primarily comprised of intangible and other liabilities at both March 31, 2018 and December 31, 2017 . RIDEA II Sale Transaction In January 2017, the Company completed the contribution of its ownership interest in RIDEA II to an unconsolidated JV owned by HCP and an investor group led by Columbia Pacific Advisors, LLC (“CPA”) (“HCP/CPA PropCo” and “HCP/CPA OpCo,” together, the “HCP/CPA JV”). Also in January 2017, RIDEA II was recapitalized with $602 million of debt, of which $360 million was provided by a third-party and $242 million was provided by HCP. In return for both transaction elements, the Company received combined proceeds of $480 million from the HCP/CPA JV and $242 million in loan receivables and retained an approximately 40% ownership interest in RIDEA II (the note receivable and 40% ownership interest are herein referred to as the “RIDEA II Investments”). This transaction resulted in the Company deconsolidating the net assets of RIDEA II and recognizing a net gain on sale of $99 million . The RIDEA II Investments are currently recognized and accounted for as equity method investments. Refer to Note 2 for the impact of adopting the Revenue ASUs on January 1, 2018 to the Company’s partial sale of RIDEA II in the first quarter of 2017. On November 1, 2017, the Company entered into a definitive agreement with an investor group led by CPA to sell its remaining 40% ownership interest in RIDEA II for $91 million . The Company expects the transaction to close in the second quarter of 2018. CPA has also agreed to cause refinancing of the Company’s $242 million loan receivables from RIDEA II within one year following the close of the transaction. U.K. Portfolio On May 1, 2018, the Company entered into definitive agreements with an institutional investor to create a joint venture (the “U.K. JV”) through which the Company will sell a 51% interest in all United Kingdom (“U.K.”) assets owned by the Company (“the U.K. Portfolio”) based on a total value of £394 million . The Company will retain a 49% noncontrolling interest in the joint venture. Upon closing the U.K. JV, the Company expects to deconsolidate the U.K. Portfolio and recognize a gain on deconsolidation. 2018 Dispositions In January 2018, the Company sold two SHOP assets for $35 million , resulting in gain on sales of $21 million . In April 2018, the Company sold four SHOP assets and two senior housing triple-net assets for $265 million . 2017 Dispositions (Three months ended March 31, 2017) In January 2017, the Company sold four life science facilities in Salt Lake City, Utah for $76 million , resulting in a net gain on sale of $45 million . In March 2017, the Company sold 64 senior housing triple-net assets, previously under triple-net leases with Brookdale, for $1.125 billion to affiliates of Blackstone Real Estate Partners VIII, L.P., resulting in a net gain on sale of $170 million . Investments in Real Estate During the three months ended March 31, 2018, the Company acquired development rights on a land parcel in the Boston suburb of Lexington, Massachusetts for $ 21 million . The Company will commence a life science development on the land in 2018. There were no new real estate investments made during the three months ended March 31, 2017. |
Net Investment in Direct Financ
Net Investment in Direct Financing Leases | 3 Months Ended |
Mar. 31, 2018 | |
Leases, Capital [Abstract] | |
Net Investment in Direct Financing Leases | Net Investment in Direct Financing Leases Net investment in DFLs consisted of the following (dollars in thousands): March 31, December 31, Minimum lease payments receivable $ 1,049,400 $ 1,062,452 Estimated residual value 504,457 504,457 Less unearned income (840,394 ) (852,557 ) Net investment in direct financing leases $ 713,463 $ 714,352 Properties subject to direct financing leases 29 29 In February 2017, the Company sold a hospital within a DFL in Palm Beach Gardens, Florida for $43 million to the current tenant and recognized a gain on sale of $4 million . Direct Financing Lease Internal Ratings The following table summarizes the Company’s internal ratings for DFLs at March 31, 2018 (dollars in thousands): Carrying Amount Percentage of DFL Portfolio Internal Ratings Segment Performing DFLs Watch List DFLs Workout DFLs Senior housing triple-net $ 628,859 88 $ 274,264 $ 354,595 $ — Other non-reportable segments 84,604 12 84,604 — — $ 713,463 100 $ 358,868 $ 354,595 $ — Beginning September 30, 2013, the Company placed a 14 -property senior housing triple-net DFL (the “DFL Watchlist Portfolio”) on nonaccrual status and “Watch List” status. The Company determined that the collection of all rental payments was and continues to be no longer reasonably assured; therefore, rental revenue for the DFL Watchlist Portfolio is being recognized on a cash basis. During the three months ended March 31, 2018 and 2017 , the Company recognized income from DFLs of $3 million and received cash payments of $5 million and $4 million , respectively, from the DFL Watchlist Portfolio. The carrying value of the DFL Watchlist Portfolio was $355 million and $356 million at March 31, 2018 and December 31, 2017 , respectively. |
Loans Receivable
Loans Receivable | 3 Months Ended |
Mar. 31, 2018 | |
Receivables [Abstract] | |
Loans Receivable | Loans Receivable The following table summarizes the Company’s loans receivable (in thousands): March 31, 2018 December 31, 2017 Real Estate Secured Other Secured Total Real Estate Secured Other Secured Total Mezzanine (1) $ — $ 22,105 $ 22,105 $ — $ 269,299 $ 269,299 Other (2) 24,990 — 24,990 188,418 — 188,418 Unamortized discounts, fees and costs — (83 ) (83 ) — (596 ) (596 ) Allowance for loan losses (3) — — — — (143,795 ) (143,795 ) $ 24,990 $ 22,022 $ 47,012 $ 188,418 $ 124,908 $ 313,326 _______________________________________ (1) In December 2017, the Company entered into a participating debt financing arrangement to fund a $115 million senior living development project, which remained unfunded at March 31, 2018 . (2) Represents loans denominated in British pound sterling (“GBP”). At December 31, 2017 , includes the U.K. Bridge Loan discussed below. (3) Related to the Company’s mezzanine loan facility to Tandem Health Care discussed below. Loans Receivable Internal Ratings The following table summarizes the Company’s internal ratings for loans receivable at March 31, 2018 (dollars in thousands): Carrying Amount Percentage of Loan Portfolio Internal Ratings Investment Type Performing Loans Watch List Loans Workout Loans Real estate secured $ 24,990 53 $ 24,990 $ — $ — Other secured 22,022 47 22,022 — — $ 47,012 100 $ 47,012 $ — $ — Four Seasons Health Care In March 2017, the Company sold its investment in Four Seasons Health Care’s (“Four Seasons”) senior secured term loan at par plus accrued interest for £29 million ( $35 million ). Additionally, in March 2017, pursuant to a shift in the Company’s investment strategy, the Company sold its £138.5 million par value Four Seasons senior notes (the “Four Seasons Notes”) for £83 million ( $101 million ). The disposition of the Four Seasons Notes generated a £42 million ( $51 million ) gain on sale, recognized in other income (expense), net, as the sales price was above the previously-impaired carrying value of £41 million ( $50 million ). HC-One Facility On June 30, 2017, the Company received £283 million ( $367 million ) from the repayment of its HC-One mezzanine loan. Tandem Health Care Loan From July 2012 through May 2015, the Company funded, in aggregate, $257 million under a collateralized mezzanine loan facility (the “Mezzanine Loan”) to certain affiliates of Tandem Health Care (together with its affiliates, “Tandem”). During 2017, the Company recorded impairment charges totaling $144 million on the Mezzanine Loan. The decline in fair value driving each impairment charge was based primarily on declining operating results of the collateral underlying the Mezzanine Loan, as well as market and industry data, which reflected a declining trend in admissions and a continuing shift away from higher-rate Medicare plans in the post-acute/skilled nursing sector. The resulting carrying value of the Mezzanine Loan as of December 31, 2017 was $105 million . In conjunction with the declining operating results and industry trends, beginning in the first quarter of 2017, the Company elected to recognize interest income on a cash basis. During the three months ended March 31, 2018 and 2017 , the Company recognized interest income and received cash payments of zero and $7 million , respectively, from Tandem. In March 2018, the Company sold the Mezzanine Loan to a third party for approximately $112 million , resulting in an impairment recovery, net of transaction costs and fees, of $3 million included in other income (expense), net. The Company holds no further economic interest in the operations of Tandem. U.K. Bridge Loan In 2016, the Company provided a £105 million ( $131 million at closing) bridge loan to Maria Mallaband Care Group Ltd. (“MMCG”) to fund the acquisition of a portfolio of seven care homes in the U.K. Under the bridge loan, the Company retained a three -year call option to acquire those seven care homes at a future date for £105 million , subject to certain conditions precedent being met. In March 2018, upon resolution of all conditions precedent, the Company began the process of exercising its call option to acquire the seven care homes and concluded that it should consolidate the real estate. As a result, the Company derecognized the outstanding loan receivable of £105 million and recognized a £29 million ( $41 million ) loss on consolidation. Refer to Note 15 for the complete impact of consolidating the seven care homes during the first quarter of 2018. |
Investments in and Advances to
Investments in and Advances to Unconsolidated Joint Ventures | 3 Months Ended |
Mar. 31, 2018 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Investments in and Advances to Unconsolidated Joint Ventures | Investments in and Advances to Unconsolidated Joint Ventures The Company owns interests in the following entities that are accounted for under the equity method (dollars in thousands): Carrying Amount March 31, December 31, Entity (1) Ownership% 2018 2017 CCRC JV 49 $ 395,005 $ 400,241 RIDEA II (2) 40 328,873 259,651 Life Science JVs (3) 50 - 63 65,016 65,581 MBK JV 50 37,442 38,005 Development JVs (4) 50 - 90 23,733 23,365 Medical Office JVs (5) 20 - 67 12,395 12,488 K&Y JVs (6) 80 1,298 1,283 Advances to unconsolidated joint ventures, net 13 226 $ 863,775 $ 800,840 _______________________________________ (1) These entities are not consolidated because the Company does not control, through voting rights or other means, the JVs. (2) Effective January 1, 2018, the Company increased its carrying value in RIDEA II as a net adjustment to retained earnings under its elected transition approach in accordance with the adoption of ASU 2017-05 (see Note 2). See Note 4 for further information on the deconsolidation and pending sale of RIDEA II. (3) Includes the following unconsolidated partnerships (and the Company’s ownership percentage): (i) Torrey Pines Science Center, LP ( 50% ); (ii) Britannia Biotech Gateway, LP ( 55% ); and (iii) LASDK, LP ( 63% ). (4) Includes four unconsolidated SHOP development partnerships (and the Company’s ownership percentage): (i) Vintage Park Development JV ( 85% ); (ii) Waldwick JV ( 85% ); (iii) Otay Ranch JV ( 90% ); and (iv) MBK Development JV ( 50% ). (5) Includes three unconsolidated medical office partnerships (and the Company’s ownership percentage): HCP Ventures IV, LLC ( 20% ); HCP Ventures III, LLC ( 30% ); and Suburban Properties, LLC ( 67% ). (6) Includes three unconsolidated JVs. |
Intangibles
Intangibles | 3 Months Ended |
Mar. 31, 2018 | |
Intangibles | |
Intangibles | Intangibles Intangible assets primarily consist of lease-up intangibles, above market tenant lease intangibles and below market ground lease intangibles. Intangible liabilities primarily consist of below market lease intangibles and above market ground lease intangibles. The following tables summarize the Company’s intangible lease assets and liabilities (in thousands): Intangible lease assets March 31, December 31, Gross intangible lease assets $ 732,110 $ 795,305 Accumulated depreciation and amortization (336,812 ) (385,223 ) Intangible assets, net $ 395,298 $ 410,082 Intangible lease liabilities March 31, December 31, Gross intangible lease liabilities $ 124,609 $ 126,212 Accumulated depreciation and amortization (72,033 ) (73,633 ) Intangible liabilities, net $ 52,576 $ 52,579 |
Debt
Debt | 3 Months Ended |
Mar. 31, 2018 | |
Debt Disclosure [Abstract] | |
Debt | Debt Bank Line of Credit and Term Loan The Company’s $2.0 billion unsecured revolving line of credit facility (the “Facility”) matures on October 19, 2021 and contains two , six -month extension options. Borrowings under the Facility accrue interest at LIBOR plus a margin that depends on the Company’s credit ratings. The Company pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company’s credit ratings at March 31, 2018 , the margin on the Facility was 1.00% and the facility fee was 0.20% . The Facility also includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to $750 million , subject to securing additional commitments. At March 31, 2018 , the Company had $1.1 billion , including £105 million ( $147 million ), outstanding under the Facility, with a weighted average effective interest rate of 2.99% . On April 6, 2018, the Company paid down $290 million outstanding under the Facility primarily using proceeds from asset sales to Brookdale (see Note 3). At March 31, 2018 , the Company had £169 million ( $237 million ) outstanding on its term loan, which accrues interest at a rate of GBP LIBOR plus 1.15% , subject to adjustments based on the Company’s credit ratings. The term loan matures in January 2019 and contains a one -year committed extension option. The Company has a one-time right to repay the outstanding GBP balance and re-borrow in USD with all other key terms unchanged. The Facility and term loan contain certain financial restrictions and other customary requirements, including cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the agreements: (i) limit the ratio of Consolidated Total Indebtedness to Consolidated Total Asset Value to 60% ; (ii) limit the ratio of Secured Debt to Consolidated Total Asset Value to 30% ; (iii) limit the ratio of Unsecured Debt to Consolidated Unencumbered Asset Value to 60% ; (iv) require a minimum Fixed Charge Coverage ratio of 1.5 times; and (v) require a Minimum Consolidated Tangible Net Worth of $6.5 billion . At March 31, 2018 , the Company was in compliance with each of these restrictions and requirements of the Facility and term loan. Senior Unsecured Notes At March 31, 2018 , the Company had senior unsecured notes outstanding with an aggregate principal balance of $6.5 billion . The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions and other customary terms. The Company believes it was in compliance with these covenants at March 31, 2018 . The following table summarizes the Company’s senior unsecured notes payoffs during the year ended December 31, 2017 (dollars in thousands): Date Amount Coupon Rate May 1, 2017 $ 250,000 5.625 % July 27, 2017 $ 500,000 5.375 % There were no senior unsecured notes repayments during the three months ended March 31, 2018 . There were no senior unsecured notes issuances during the three months ended March 31, 2018 or year ended December 31, 2017 . Mortgage Debt At March 31, 2018 , the Company had $138 million in aggregate principal of mortgage debt outstanding, which is secured by 16 healthcare facilities (including redevelopment properties) with a carrying value of $296 million . In March 2017, the Company paid off $472 million of mortgage debt. Mortgage debt generally requires monthly principal and interest payments, is collateralized by real estate assets and is generally non-recourse. Mortgage debt typically restricts transfer of the encumbered assets, prohibits additional liens, restricts prepayment, requires payment of real estate taxes, requires maintenance of the assets in good condition, requires maintenance of insurance on the assets and includes conditions to obtain lender consent to enter into or terminate material leases. Some of the mortgage debt may require tenants or operators to maintain compliance with the applicable leases or operating agreements of such real estate assets. Debt Maturities The following table summarizes the Company’s stated debt maturities and scheduled principal repayments at March 31, 2018 (in thousands): Year Bank Line of Credit (1) Term Loan (2) Senior Unsecured Notes (3) Mortgage Debt (4) Total (5) 2018 (nine months) $ — $ — $ — $ 2,649 $ 2,649 2019 — 237,175 450,000 3,700 690,875 2020 — — 800,000 3,758 803,758 2021 1,092,357 — 700,000 11,117 1,803,474 2022 — — 900,000 2,861 902,861 Thereafter — — 3,600,000 113,619 3,713,619 1,092,357 237,175 6,450,000 137,704 7,917,236 (Discounts), premium and debt costs, net — (297 ) (51,024 ) 5,820 (45,501 ) $ 1,092,357 $ 236,878 $ 6,398,976 $ 143,524 $ 7,871,735 _______________________________________ (1) Includes £105 million translated into U.S. dollars (“USD”). (2) Represents £169 million translated into USD. (3) Effective interest rates on the notes ranged from 2.79% to 6.88% with a weighted average effective interest rate of 4.20% and a weighted average maturity of six years . (4) Interest rates on the mortgage debt ranged from 1.95% to 5.91% with a weighted average effective interest rate of 4.18% and a weighted average maturity of 20 years . (5) Excludes $94 million of other debt that have no scheduled maturities. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2018 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Legal Proceedings From time to time, the Company is a party to, or has a significant relationship to, legal proceedings, lawsuits and other claims. Except as described below, the Company is not aware of any legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company’s financial condition, results of operations or cash flows. The Company’s policy is to expense legal costs as they are incurred. Class Action. On May 9, 2016, a purported stockholder of the Company filed a putative class action complaint, Boynton Beach Firefighters’ Pension Fund v. HCP, Inc., et al ., Case No. 3:16-cv-01106-JJH, in the U.S. District Court for the Northern District of Ohio against the Company, certain of its officers, HCR ManorCare, Inc. (“HCRMC”), and certain of its officers, asserting violations of the federal securities laws. The suit asserts claims under sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and alleges that the Company made certain false or misleading statements relating to the value of and risks concerning its investment in HCRMC by allegedly failing to disclose that HCRMC had engaged in billing fraud, as alleged by the U.S. Department of Justice in a pending suit against HCRMC arising from the False Claims Act. The plaintiff in the suit demands compensatory damages (in an unspecified amount), costs and expenses (including attorneys’ fees and expert fees), and equitable, injunctive, or other relief as the Court deems just and proper. On November 28, 2017, the Court appointed Societe Generale Securities GmbH (SGSS Germany) and the City of Birmingham Retirement and Relief Systems (Birmingham) as Co-Lead Plaintiffs in the class action. Co-Lead Plaintiffs filed a consolidated Amended Complaint on February 28, 2018. Defendants filed their motion to dismiss the Amended Complaint on March 30, 2018. The Company believes the suit to be without merit and intends to vigorously defend against it. Derivative Actions. On June 16, 2016 and July 5, 2016, purported stockholders of the Company filed two derivative actions, respectively Subodh v. HCR ManorCare Inc., et al. , Case No. 30-2016-00858497-CU-PT-CXC and Stearns v. HCR ManorCare, Inc., et al. , Case No. 30-2016-00861646-CU-MC-CJC, in the Superior Court of California, County of Orange, against certain of the Company’s current and former directors and officers and HCRMC. The Company is named as a nominal defendant. As both derivative actions contained substantially the same allegations, they have been consolidated into a single action. The consolidated action alleges that the defendants engaged in various acts of wrongdoing, including, among other things, breaching fiduciary duties by publicly making false or misleading statements of fact regarding HCRMC’s finances and prospects, and failing to maintain adequate internal controls. As the Subodh/Stearns action is in the early stages, defendants have not yet responded to the complaint. On April 18, 2017, the Court approved the parties’ stipulation staying the action pending further developments, including in the related securities class action litigation. The Court recently adjourned the status conference scheduled for January 10, 2018 to June 11, 2018. On April 10, 2017, a purported stockholder of the Company filed a derivative action, Weldon v. Martin et al. , Case No. 3:17-cv-755, in federal court in the Northern District of Ohio, Western Division, against certain of the Company’s current and former directors and officers and HCRMC. The Company is named as a nominal defendant. The Weldon complaint asserts similar claims to those asserted in the California derivative actions. In addition, the complaint asserts a claim under Section 14(a) of the Exchange Act, alleging that the Company made false statements in its 2016 proxy statement by not disclosing that the Company’s performance issues in 2015 were the direct result of billing fraud at HCRMC. On April 18, 2017, the Court re-assigned and transferred this action to the judge presiding over the related federal securities class action. Defendants have not yet been served or responded to the complaint. On July 11, 2017, the Court approved a stipulation by the parties to stay the case pending disposition of the motion to dismiss the class action. On July 21, 2017, a purported stockholder of the Company filed another derivative action, Kelley v. HCR ManorCare, Inc., et al. , Case No. 8:17-cv-01259, in federal court in the Central District of California, against certain of the Company’s current and former directors and officers and HCRMC. The Company is named as a nominal defendant. The Kelley complaint asserts similar claims to those asserted in Weldon and in the California derivative actions. Like Weldon , the Kelley complaint also additionally alleges that the Company made false statements in its 2016 proxy statement, and asserts a claim for a violation of Section 14(a) of the Exchange Act. On September 25, 2017, Defendants moved to transfer the action to the Northern District of Ohio ( i.e. , the court where the class action and other federal derivative action are pending) or, in the alternative, to stay the action. The Court granted Defendants’ motion to transfer on November 28, 2017, and Kelley is now pending in the Northern District of Ohio. The Court in the Northern District of Ohio is considering a request to consolidate the Weldon and Kelley actions. The Company’s Board of Directors received letters dated August 17, 2016, April 19, 2017, and April 20, 2017 from private law firms acting on behalf of clients who are purported stockholders of the Company, each asserting allegations similar to those made in the Subodh and Stearns matters discussed above. Each letter demands that the Board of Directors take action to assert the Company’s rights. The Board of Directors completed its evaluation and determined to reject the demand letters. Rejection notices were sent in December of 2017. The Company believes that the plaintiffs lack standing or the lawsuits and demands are without merit, and the Company is unable to estimate the amount of loss or range of reasonably possible losses with respect to the matters discussed above as of March 31, 2018 . |
Equity
Equity | 3 Months Ended |
Mar. 31, 2018 | |
Equity [Abstract] | |
Equity | Equity Accumulated Other Comprehensive Income (Loss) The following table summarizes the Company’s accumulated other comprehensive income (loss) (in thousands): March 31, December 31, Cumulative foreign currency translation adjustment $ 697 $ (6,955 ) Unrealized gains (losses) on cash flow hedges, net (18,989 ) (13,950 ) Supplemental Executive Retirement plan minimum liability and other (3,015 ) (3,119 ) Total other comprehensive income (loss) $ (21,307 ) $ (24,024 ) Noncontrolling Interests See Note 4 for the deconsolidation of RIDEA II and Note 14 for the supplemental schedule of non-cash financing activities. See Note 3 for the Company’s purchase of Brookdale’s noncontrolling interest in RIDEA III in March 2018. |
Segment Disclosures
Segment Disclosures | 3 Months Ended |
Mar. 31, 2018 | |
Segment Reporting [Abstract] | |
Segment Disclosures | Segment Disclosures The Company evaluates its business and allocates resources based on its reportable business segments: (i) senior housing triple-net, (ii) SHOP, (iii) life science and (iv) medical office. The Company has non-reportable segments that are comprised primarily of the Company’s debt investments, hospital properties, unconsolidated JVs (see below) and care homes in the U.K. The accounting policies of the segments are the same as those in Note 2 to the Consolidated Financial Statements in the Company’s 2017 Annual Report on Form 10-K filed with the SEC, as updated by Note 2 herein. During the three months ended March 31, 2018 , there were no transfers of assets between segments. During the three months ended March 31, 2017 , one senior housing triple-net facility was transferred to the Company’s SHOP segment. The Company evaluates performance based upon: (i) property NOI and (ii) Adjusted NOI. NOI is defined as rental and related revenues, including tenant recoveries, resident fees and services, and income from DFLs, less property level operating expenses (which exclude transition costs); NOI excludes all other financial statement amounts included in net income (loss) . Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, termination fees, and the impact of deferred community fee income and expense. During the fourth quarter of 2017, as a result of a change in how operating results are reported to the chief operating decision makers, for the purpose of evaluating performance and allocating resources, the Company began excluding unconsolidated JVs from its evaluation of its segments' operating results. Unconsolidated JVs are now reflected in other non-reportable segments. The adjustments to NOI and resulting Adjusted NOI for SHOP have been recast for prior periods to conform to the current period presentation which excludes: (i) the impact of deferred community fee income and expense, resulting in recognition as cash is received and expenses are paid and (ii) adjustments related to unconsolidated JVs (see above). Non-segment assets consist of assets in the Company's other non-reportable segments and corporate non-segment assets. Corporate non-segment assets consist primarily of corporate assets, including cash and cash equivalents, restricted cash, accounts receivable, net, marketable equity securities and, if any, real estate assets and liabilities held for sale. See Note 16 for other information regarding concentrations of credit risk. The following tables summarize information for the reportable segments (in thousands): For the three months ended March 31, 2018 : Senior Housing Triple-Net SHOP Life Science Medical Office Other Non-reportable Corporate Non-segment Total Rental revenues (1) $ 74,289 $ 144,670 $ 99,622 $ 123,935 $ 30,316 $ — $ 472,832 Operating expenses (1,045 ) (101,746 ) (21,809 ) (46,696 ) (1,256 ) — (172,552 ) NOI 73,244 42,924 77,813 77,239 29,060 — 300,280 Adjustments to NOI (2) (1,865 ) (1,607 ) (3,751 ) (1,071 ) (1,392 ) — (9,686 ) Adjusted NOI 71,379 41,317 74,062 76,168 27,668 — 290,594 Addback adjustments 1,865 1,607 3,751 1,071 1,392 — 9,686 Interest income — — — — 6,365 — 6,365 Interest expense (600 ) (988 ) (83 ) (120 ) (728 ) (72,583 ) (75,102 ) Depreciation and amortization (21,906 ) (27,628 ) (36,080 ) (45,519 ) (12,117 ) — (143,250 ) General and administrative — — — — — (29,175 ) (29,175 ) Transaction costs — — — — — (2,195 ) (2,195 ) Gain (loss) on sales of real estate, net — 20,815 — — — — 20,815 Other income (expense), net — — — — (40,567 ) 160 (40,407 ) Income tax benefit (expense) — — — — — 5,336 5,336 Equity income (loss) from unconsolidated JVs — — — — 570 — 570 Net income (loss) $ 50,738 $ 35,123 $ 41,650 $ 31,600 $ (17,417 ) $ (98,457 ) $ 43,237 _______________________________________ (1) Represents rental and related revenues, tenant recoveries, resident fees and services, and income from DFLs. (2) Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, deferral of community fees, net and termination fees. For the three months ended March 31, 2017 : Senior Housing Triple-Net SHOP Life Science Medical Office Other Non-reportable Corporate Non-segment Total Rental revenues (1) $ 100,034 $ 140,228 $ 85,321 $ 118,371 $ 29,883 $ — $ 473,837 Operating expenses (1,111 ) (94,539 ) (17,319 ) (44,864 ) (1,248 ) — (159,081 ) NOI 98,923 45,689 68,002 73,507 28,635 — 314,756 Adjustments to NOI (2) (1,839 ) (310 ) (305 ) (961 ) (1,012 ) — (4,427 ) Adjusted NOI 97,084 45,379 67,697 72,546 27,623 — 310,329 Addback adjustments 1,839 310 305 961 1,012 — 4,427 Interest income — — — — 18,331 — 18,331 Interest expense (627 ) (4,596 ) (104 ) (129 ) (1,997 ) (79,265 ) (86,718 ) Depreciation and amortization (26,411 ) (26,358 ) (33,791 ) (42,729 ) (7,265 ) — (136,554 ) General and administrative — — — — — (22,478 ) (22,478 ) Transaction costs — — — — — (1,057 ) (1,057 ) Gain (loss) on sales of real estate, net 268,464 366 44,633 — 3,795 — 317,258 Other income (expense), net — — — — 50,895 313 51,208 Income tax benefit (expense) — — — — — 6,162 6,162 Equity income (loss) from unconsolidated JVs — — — — 3,269 — 3,269 Net income (loss) $ 340,349 $ 15,101 $ 78,740 $ 30,649 $ 95,663 $ (96,325 ) $ 464,177 _______________________________________ (1) Represents rental and related revenues, tenant recoveries, resident fees and services, and income from DFLs. (2) Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, deferral of community fees, net and termination fees. The following table summarizes the Company’s revenues by segment (in thousands): Three Months Ended March 31, Segment 2018 2017 Senior housing triple-net $ 74,289 $ 100,034 SHOP 144,670 140,228 Life science 99,622 85,321 Medical office 123,935 118,371 Other non-reportable segments 36,681 48,214 Total revenues $ 479,197 $ 492,168 See Notes 3, 4 and 6 for significant transactions impacting the Company’s segment assets during the periods presented. |
Earnings Per Common Share
Earnings Per Common Share | 3 Months Ended |
Mar. 31, 2018 | |
Earnings Per Share [Abstract] | |
Earnings Per Common Share | Earnings Per Common Share The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts): Three Months Ended 2018 2017 Numerator Net income (loss) from continuing operations $ 43,237 $ 464,177 Noncontrolling interests' share in earnings (3,005 ) (3,032 ) Net income (loss) attributable to HCP, Inc. 40,232 461,145 Less: Participating securities' share in earnings (391 ) (770 ) Net income (loss) applicable to common shares $ 39,841 $ 460,375 Numerator - Dilutive Net income (loss) applicable to common shares $ 39,841 $ 460,375 Add: distributions on dilutive convertible units and other — 2,803 Dilutive net income (loss) available to common shares $ 39,841 $ 463,178 Denominator Basic weighted average shares outstanding 469,557 468,299 Dilutive potential common shares - equity awards 138 229 Dilutive potential common shares - DownREIT conversions — 6,645 Diluted weighted average common shares 469,695 475,173 Earnings per common share: Basic $ 0.08 $ 0.98 Diluted $ 0.08 $ 0.97 Restricted stock and certain performance restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, and require use of the two-class method when computing basic and diluted earnings per share. For the three months ended March 31, 2018 , 7 million shares issuable upon conversion of 4 million DownREIT units were not included because they are anti-dilutive. |
Supplemental Cash Flow Informat
Supplemental Cash Flow Information | 3 Months Ended |
Mar. 31, 2018 | |
Supplemental Cash Flow Elements [Abstract] | |
Supplemental Cash Flow Information | Supplemental Cash Flow Information The following table provides supplemental cash flow information (in thousands): Three Months Ended March 31, 2018 2017 Supplemental cash flow information: Interest paid, net of capitalized interest $ 92,701 $ 108,232 Income taxes paid 340 1,105 Capitalized interest 3,578 3,090 Supplemental schedule of non-cash investing and financing activities: Accrued construction costs 62,160 51,498 Derecognition of U.K. Bridge Loan receivable 147,474 — Consolidation of net assets related to U.K. Bridge Loan 106,457 — Deconsolidation of noncontrolling interest in connection with RIDEA II transaction — 58,061 Vesting of restricted stock units and conversion of non-managing member units into common stock 258 1,841 See discussions related to the U.K. Bridge Loan in Notes 6 and 15. The following table summarizes cash, cash equivalents and restricted cash (in thousands): March 31, 2018 2017 Cash and cash equivalents $ 86,021 $ 764,114 Restricted cash 31,947 60,806 Cash, cash equivalents and restricted cash $ 117,968 $ 824,920 |
Variable Interest Entities
Variable Interest Entities | 3 Months Ended |
Mar. 31, 2018 | |
Variable Interest Entities [Abstract] | |
Variable Interest Entities | Variable Interest Entities Unconsolidated Variable Interest Entities At March 31, 2018 , the Company had investments in: (i) five unconsolidated VIE JVs, (ii) 48 properties leased to VIE tenants, (iii) marketable debt securities of one VIE and (iv) one loan to a VIE borrower. The Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs because it does not have the ability to control the activities that most significantly impact their economic performance. Except for the Company’s equity interest in the unconsolidated JVs (CCRC OpCo, RIDEA II PropCo, Vintage Park Development JV, Waldwick JV and the LLC investment discussed below), it has no formal involvement in these VIEs beyond its investments. The Company holds a 49% ownership interest in CCRC OpCo, a JV entity formed in August 2014 that operates senior housing properties in a RIDEA structure and has been identified as a VIE (see Note 7). The equity members of CCRC OpCo “lack power” because they share certain operating rights with Brookdale, as manager of the CCRCs. The assets of CCRC OpCo primarily consist of the CCRCs that it owns and leases, resident fees receivable, notes receivable, and cash and cash equivalents; its obligations primarily consist of operating lease obligations to CCRC PropCo, debt service payments and capital expenditures for the properties, and accounts payable and expense accruals associated with the cost of its CCRCs’ operations. Assets generated by the CCRC operations (primarily rents from CCRC residents) of CCRC OpCo may only be used to settle its contractual obligations (primarily from debt service payments, capital expenditures, and rental costs and operating expenses incurred to manage such facilities). In January 2017, as a result of the partial sale of its interest in RIDEA II, the Company concluded that it should deconsolidate RIDEA II as it is no longer the primary beneficiary of the JV. The HCP/CPA JV is the primary beneficiary of both RIDEA II PropCo and RIDEA II OpCo as it controls the significant activities of RIDEA II PropCo and, of the group that controls the significant activities of RIDEA II OpCo, is most closely associated to the entity. Furthermore, control over the HCP/CPA JV is shared between HCP and CPA, and as such, the Company does not consolidate the HCP/CPA JV. Subsequent to the partial sale of its interest in RIDEA II, the Company continues to hold a direct investment in RIDEA II PropCo, which has been identified as a VIE as Brookdale, the non-managing member, does not have any substantive participating rights or kick-out rights over the managing member, HCP/CPA PropCo (see Notes 4 and 7). The assets of RIDEA II PropCo primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of a combination of third-party and HCP debt (see Note 4). Assets generated by RIDEA II PropCo (primarily from RIDEA II OpCo lease payments) may only be used to settle its contractual obligations (primarily debt service payments on the third-party and HCP debt). The Company holds an 85% ownership interest in a JV (Vintage Park Development JV) (see Note 7), which has been identified as a VIE as power is shared with a member that does not have a substantive equity investment at risk. The assets of the JV primarily consist of a leased property (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of debt-service payments. Any assets generated by the JV may only be used to settle its respective contractual obligations (primarily debt service payments). The Company holds an 85% ownership interest in a development JV (Waldwick JV) (see Note 7), which has been identified as a VIE as power is shared with a member that does not have a substantive equity investment at risk. The assets of the JV primarily consist of an in-progress senior housing facility development project that it owns and cash and cash equivalents; its obligations primarily consist of accounts payable and expense accruals associated with the cost of its development obligations. Any assets generated by the JV may only be used to settle its respective contractual obligations (primarily development expenses and debt service payments). The Company holds a limited partner ownership interest in an unconsolidated LLC that has been identified as a VIE. The Company’s involvement in the entity is limited to its equity investment as a limited partner, and it does not have any substantive participating rights or kick-out rights over the general partner. The assets and liabilities of the entity primarily consist of those associated with its senior housing real estate and development activities. Any assets generated by the entity may only be used to settle its contractual obligations (primarily development expenses and debt service payments). The Company leases 48 properties to a total of seven tenants that have also been identified as VIEs (“VIE tenants”). These VIE tenants are “thinly capitalized” entities that rely on the operating cash flows generated from the senior housing facilities to pay operating expenses, including the rent obligations under their leases. The Company holds commercial mortgage-backed securities (“CMBS”) issued by Federal Home Loan Mortgage Corporation (commonly referred to as Freddie MAC) through a special purpose entity that has been identified as a VIE because it is “thinly capitalized.” The CMBS issued by the VIE are backed by mortgage debt obligations on real estate assets. The Company provided seller financing of $10 million related to its sale of seven senior housing triple-net facilities. The financing was provided in the form of a secured five -year mezzanine loan to a “thinly capitalized” borrower created to acquire the facilities. The classification of the related assets and liabilities and the maximum loss exposure as a result of the Company’s involvement with these VIEs at March 31, 2018 was as follows (in thousands): VIE Type Asset/Liability Type Maximum Loss Exposure and Carrying Amount (1) VIE tenants - DFLs (2) Net investment in DFLs $ 600,822 VIE tenants - operating leases (2) Lease intangibles, net and straight-line rent receivables 5,983 CCRC OpCo Investments in unconsolidated joint ventures 190,662 RIDEA II PropCo Investments in unconsolidated joint ventures 309,882 Unconsolidated Development JVs Investments in unconsolidated joint ventures 13,070 Loan - Seller Financing Loans receivable, net 10,000 CMBS and LLC investment Marketable debt and cost method investment 33,874 _______________________________________ (1) The Company’s maximum loss exposure represents the aggregate carrying amount of such investments (including accrued interest). (2) The Company’s maximum loss exposure may be mitigated by re-leasing the underlying properties to new tenants upon an event of default. At March 31, 2018 , the Company had not provided, and is not required to provide, financial support through a liquidity arrangement or otherwise, to its unconsolidated VIEs, including circumstances in which it could be exposed to further losses (e.g., cash shortfalls). See Notes 5, 6 and 7 for additional descriptions of the nature, purpose and operating activities of the Company’s unconsolidated VIEs and interests therein. Consolidated Variable Interest Entities HCP, Inc.’s consolidated total assets and total liabilities at March 31, 2018 and December 31, 2017 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to HCP, Inc. Total assets and total liabilities include VIE assets and liabilities as follows (in thousands): March 31, 2018 December 31, 2017 Assets Buildings and improvements $ 1,744,402 $ 2,436,414 Development costs and construction in progress 16,226 32,285 Land 170,889 227,162 Accumulated depreciation and amortization (345,331 ) (542,091 ) Net real estate 1,586,186 2,153,770 Investments in and advances to unconsolidated joint ventures 2,148 2,231 Accounts receivable, net 7,287 10,242 Cash and cash equivalents 12,077 15,861 Restricted cash 2,595 2,619 Intangible assets, net 111,149 125,475 Other assets, net 35,788 33,749 Total assets $ 1,757,230 $ 2,343,947 Liabilities Mortgage debt 44,882 45,016 Intangible liabilities, net 12,509 10,672 Accounts payable and accrued liabilities 223,708 269,280 Deferred revenue 15,275 14,432 Total liabilities $ 296,374 $ 339,400 HCP Ventures V, LLC . The Company holds a 51% ownership interest in and is the managing member of a JV entity formed in October 2015 that owns and leases medical office buildings (“MOBs”) (“HCP Ventures V”). Upon adoption of ASU 2015-02, the Company classified HCP Ventures V as a VIE due to the non-managing member lacking substantive participation rights in the management of HCP Ventures V or kick-out rights over the managing member. The Company consolidates HCP Ventures V as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of HCP Ventures V primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by HCP Ventures V may only be used to settle its contractual obligations (primarily from capital expenditures). Vintage Park JV. The Company holds a 90% ownership interest in a JV entity formed in January 2015 (“Vintage Park JV”) that owns an 85% interest in an unconsolidated development VIE. Upon adoption of ASU 2015-02, the Company classified Vintage Park JV as a VIE due to the non-managing member lacking substantive participation rights in the management of the Vintage Park JV or kick-out rights over the managing member. The Company consolidates Vintage Park JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of Vintage Park JV primarily consist of an investment in the Vintage Park Development JV and cash and cash equivalents; its obligations primarily consist of funding the ongoing development of the Vintage Park Development JV. Assets generated by the Vintage Park JV may only be used to settle its contractual obligations (primarily from the funding of the Vintage Park Development JV). Watertown JV . The Company holds a 95% ownership interest in JV entities formed in November 2017 that own and operate a senior housing property in a RIDEA structure (“Watertown JV”). Watertown PropCo is a VIE as the Company and the non-managing member share in control of the entity, but substantially all of the entity's activities are performed on behalf of the Company. Watertown OpCo is a VIE as the non-managing member, through its equity interest, lacks substantive participation rights in the management of Watertown OpCo or kick-out rights over the managing member. The Company consolidates Watertown PropCo and Watertown OpCo as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of Watertown PropCo primarily consist of a leased property (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of notes payable to a non-VIE consolidated subsidiary of the Company. The assets of Watertown OpCo primarily consist of leasehold interests in a senior housing facility (operating lease), resident fees receivable, and cash and cash equivalents; its obligations primarily consist of lease payments to Watertown PropCo and operating expenses of its senior housing facilities (accounts payable and accrued expenses). Assets generated by the senior housing operations (primarily from senior housing resident rents) of the Watertown structure may only be used to settle its contractual obligations (primarily from the rental costs, operating expenses incurred to manage such facilities and debt costs). Hayden JV . The Company holds a 99% ownership interest in a JV entity formed in December 2017 that owns and leases a life science complex (“Hayden JV”). The Hayden JV is a VIE as the members share in control of the entity, but substantially all of the entity's activities are performed on behalf of the Company. The Company consolidates the Hayden JV as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the Hayden JV primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by Hayden JV may only be used to settle its contractual obligations (primarily from capital expenditures). Consolidated Lessees. The Company leases 21 senior housing properties to lessee entities under cash flow leases through which the Company receives monthly rent equal to the residual cash flows of the properties. The lessee entities are classified as VIEs as they are "thinly capitalized" entities. The Company consolidates the lessee entities as it has the ability to control the activities that most significantly impact the economic performance of the lessee entities. The lessee entities' assets primarily consist of leasehold interests in senior housing facilities (operating leases), resident fees receivable, and cash and cash equivalents; its obligations primarily consist of lease payments to the Company and operating expenses of the senior housing facilities (accounts payable and accrued expenses). Assets generated by the senior housing operations (primarily from senior housing resident rents) may only be used to settle its contractual obligations (primarily from the rental costs, operating expenses incurred to manage such facilities and debt costs). DownREITs . The Company holds a controlling ownership interest in and is the managing member of five limited liability companies (“DownREITs”). The Company classifies the DownREITs as VIEs due to the non-managing members lacking substantive participation rights in the management of the DownREITs or kick-out rights over the managing member. The Company consolidates the DownREITs as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the DownREITs primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the DownREITs (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures). Other Consolidated Real Estate Partnerships. The Company holds a controlling ownership interest in and is the general partner (or managing member) of multiple partnerships that own and lease real estate assets (the “Partnerships”). The Company classifies the Partnerships as VIEs due to the limited partners (non-managing members) lacking substantive participation rights in the management of the Partnerships or kick-out rights over the general partner (managing member). The Company consolidates the Partnerships as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the Partnerships primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the Partnerships (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures). U.K. Bridge Loan. In 2016, the Company provided a £105 million ( $131 million at closing) bridge loan to MMCG to fund the acquisition of a portfolio of seven care homes in the U.K. MMCG created a special purpose entity to acquire the portfolio and funded it entirely using the Company’s bridge loan. As such, the special purpose entity has been identified as a VIE because it is “thinly capitalized.” The Company retains a three -year call option to acquire all the shares of the special purpose entity, which it can only exercise upon the occurrence of certain events. During the quarter ended March 31, 2018, the Company concluded that the conditions required to exercise the call option had been met and initiated the call option process to acquire the special purpose entity, which it expects to complete during the second quarter of 2018. In conjunction with initiating the process to legally exercise its call option and the satisfaction of required contingencies, the Company concluded that it is the primary beneficiary of the special purpose entity and therefore, should consolidate the entity. As such, the Company derecognized the previously outstanding loan receivable, recognized the special purpose entity’s assets and liabilities at their respective fair values, and recognized a £29 million ( $41 million ) loss on consolidation (within other income (expense), net and income tax benefit (expense)), net of a tax benefit of £2 million ( $3 million ), to account for the difference between the carrying value of the loan receivable and the fair value of net assets and liabilities assumed. The fair value of net assets and liabilities consolidated during the first quarter of 2018 consists of £81 million ( $114 million ) of net real estate, £4 million ( $5 million ) of intangible assets, and £9 million ( $13 million ) of net deferred tax liabilities. Other consolidated VIEs. The Company made a loan to an entity that entered into a tax credit structure (“Tax Credit Subsidiary”) and a loan to an entity that made an investment in a development JV (“Development JV”) both of which are considered VIEs. The Company consolidates the Tax Credit Subsidiary and Development JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIEs’ economic performance. The assets and liabilities of the Tax Credit Subsidiary and Development JV substantially consist of a development in progress, notes receivable, prepaid expenses, notes payable, and accounts payable and accrued liabilities generated from their operating activities. Any assets generated by the operating activities of the Tax Credit Subsidiary and Development JV may only be used to settle their contractual obligations. Exchange Accommodation Titleholder . During the year ended December 31, 2017, the Company acquired a portfolio of 11 MOBs (the "acquired properties") using a reverse like-kind exchange structure pursuant to Section 1031 of the Internal Revenue Code (a "reverse 1031 exchange"). As of March 31, 2018 , the Company had not completed the reverse 1031 exchange and as such, the acquired properties remained in the possession of an Exchange Accommodation Titleholder ("EAT"). The EAT is classified as a VIE as it is a “thinly capitalized” entity. The Company consolidates the EAT because it is the primary beneficiary as it has the ability to control the activities that most significantly impact the EAT's economic performance. The properties held by the EAT are reflected as real estate with an aggregate carrying value of $153 million as of March 31, 2018 . The assets of the EAT primarily consist of a leased property (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by the EAT may only be used to settle its contractual obligations (primarily from capital expenditures). |
Concentration of Credit Risk
Concentration of Credit Risk | 3 Months Ended |
Mar. 31, 2018 | |
Risks and Uncertainties [Abstract] | |
Concentration of Credit Risk | Concentration of Credit Risk Concentrations of credit risk arise when one or more tenants, operators or obligors related to the Company’s investments are engaged in similar business activities or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to the Company, to be similarly affected by changes in economic conditions. The Company regularly monitors various segments of its portfolio to assess potential concentrations of credit risks. The following tables provide information regarding the Company’s concentrations of credit risk with respect to certain tenants: Percentage of Total Assets Total Company Senior Housing Triple-Net March 31, December 31, March 31, December 31, Tenant 2018 2017 2018 2017 Brookdale 10 10 39 39 Percentage of Revenues Total Company Senior Housing Triple-Net Three Months Ended March 31, Three Months Ended March 31, Tenant 2018 2017 2018 2017 Brookdale (1) 7 12 43 60 _______________________________________ (1) The Company's concentration with respect to Brookdale as a tenant is expected to decrease with the completion of the Brookdale Transactions (see Note 3). Includes revenues from 64 senior housing triple-net facilities that were sold in March 2017. At March 31, 2018 and December 31, 2017 , Brookdale managed or operated, in the Company’s SHOP segment, approximately 12% and 13% , respectively, of the Company’s real estate investments based on total assets. Because an operator manages the Company’s facilities in exchange for the receipt of a management fee, the Company is not directly exposed to the credit risk of its operators in the same manner or to the same extent as its triple-net tenants. At March 31, 2018 , Brookdale provided comprehensive facility management and accounting services with respect to 68 of the Company’s consolidated SHOP facilities and 62 SHOP facilities owned by its unconsolidated JVs, for which the Company or JV pay annual management fees pursuant to long-term management agreements. The Company's concentration with respect to Brookdale as an operator in its SHOP segment is expected to decrease with the completion of the Brookdale Transactions (see Note 3) and the sale of its remaining 40% ownership interest in RIDEA II (see Note 4). Most of the management agreements have terms ranging from 10 to 15 years , with three to four 5 -year renewal periods. The base management fees are 4.5% to 5.0% of gross revenues (as defined) generated by the RIDEA facilities. In addition, there are incentive management fees payable to Brookdale if operating results of the RIDEA properties exceed pre-established EBITDAR (as defined) thresholds. See Note 3 for further information on the reduction of concentration related to Brookdale. To mitigate the credit risk of leasing properties to certain senior housing and post-acute/skilled nursing operators, leases with operators are often combined into portfolios that contain cross-default terms, so that if a tenant of any of the properties in a portfolio defaults on its obligations under its lease, the Company may pursue its remedies under the lease with respect to any of the properties in the portfolio. Certain portfolios also contain terms whereby the net operating profits of the properties are combined for the purpose of securing the funding of rental payments due under each lease. |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2018 | |
Financial Instruments, Owned, at Fair Value [Abstract] | |
Fair Value Measurements | Fair Value Measurements Financial assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets are immaterial at March 31, 2018 . The table below summarizes the carrying amounts and fair values of the Company’s financial instruments (in thousands): March 31, 2018 (3) December 31, 2017 (3) Carrying Value Fair Value Carrying Value Fair Value Loans receivable, net (2) $ 47,012 $ 47,075 $ 313,326 $ 313,242 Marketable debt securities (2) 18,814 18,814 18,690 18,690 Bank line of credit (2) 1,092,357 1,092,357 1,017,076 1,017,076 Term loan (2) 236,878 236,878 228,288 228,288 Senior unsecured notes (1) 6,398,976 6,577,155 6,396,451 6,737,825 Mortgage debt (2) 143,524 137,704 144,486 125,984 Other debt (2) 93,856 93,856 94,165 94,165 Interest-rate swap liabilities (2) 1,931 1,931 2,483 2,483 Cross currency swap liability (2) 16,684 16,684 10,968 10,968 _______________________________________ (1) Level 1: Fair value calculated based on quoted prices in active markets. (2) Level 2: Fair value based on (i) for marketable debt securities, quoted prices for similar or identical instruments in active or inactive markets, respectively, or (ii) for loans receivable, net, mortgage debt, and swaps, calculated utilizing standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit, term loan and other debt, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company’s credit rating. (3) During the three months ended March 31, 2018 and year ended December 31, 2017 , there were no material transfers of financial assets or liabilities within the fair value hierarchy. |
Derivative Financial Instrument
Derivative Financial Instruments | 3 Months Ended |
Mar. 31, 2018 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Financial Instruments | Derivative Financial Instruments The following table summarizes the Company’s outstanding interest-rate and cross currency swap contracts at March 31, 2018 (dollars and GBP in thousands): Date Entered Maturity Date Hedge Designation Notional Pay Rate Receive Rate Fair Value (1) Interest rate: July 2005 (2) July 2020 Cash Flow $ 43,000 3.82% BMA Swap Index $ (1,931 ) Cross currency swap: April 2017 (3) February 2019 Net Investment £105,000 / $131,000 2.58% 3.75 % $ (16,684 ) ______________________________________ (1) Derivative assets are recorded in other assets, net and derivative liabilities are recorded in accounts payable and accrued liabilities on the consolidated balance sheets. (2) Represents three interest-rate swap contracts, which hedge fluctuations in interest payments on variable-rate secured debt due to overall changes in hedged cash flows. (3) Represents a cross currency swap to pay 2.58% on £105 million and receive 3.75% on $131 million through February 1, 2019, with an initial and final exchange of principals at origination and maturity at a rate of 1.251 USD/GBP. Hedges the risk of changes in the USD equivalent value of a portion of the Company’s net investment in its consolidated GBP subsidiaries’ attributable to changes in the USD/GBP exchange rate. The Company uses derivative instruments to mitigate the effects of interest rate and foreign currency fluctuations on specific forecasted transactions as well as recognized financial obligations or assets. Utilizing derivative instruments allows the Company to manage the risk of fluctuations in interest and foreign currency rates related to the potential impact these changes could have on future earnings and forecasted cash flows. The Company does not use derivative instruments for speculative or trading purposes. Assuming a one percentage point shift in the underlying interest rate curve, the estimated change in fair value of each of the underlying derivative instruments would not exceed $2 million . Assuming a one percentage point shift in the underlying foreign currency exchange rates, the estimated change in fair value of each of the underlying derivative instruments would not exceed $2 million . At March 31, 2018 , £150 million of the Company’s GBP-denominated borrowings under the term loan and a £105 million cross currency swap are designated as a hedge of a portion of the Company’s net investments in GBP-functional subsidiaries to mitigate its exposure to fluctuations in the GBP to USD exchange rate. For instruments that are designated and qualify as net investment hedges, the variability in the foreign currency to USD exchange rate of the instrument is recorded as part of the cumulative translation adjustment component of accumulated other comprehensive income (loss). Accordingly, (i) the remeasurement value of the designated £150 million GBP-denominated borrowings and (ii) the change in fair value of the £105 million cross currency swap due primarily to fluctuations in the GBP to USD exchange rate are reported in accumulated other comprehensive income (loss) as the hedging relationship is considered to be effective. The balance in accumulated other comprehensive income (loss) will be reclassified to earnings when the hedged investment is sold or substantially liquidated. |
Summary of Significant Accoun27
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2018 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from management’s estimates. The consolidated financial statements include the accounts of HCP, Inc., its wholly-owned subsidiaries, joint ventures (“JVs”) and variable interest entities (“VIEs”) that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations and cash flows have been included. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 . The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”). |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Revenue Recognition. Between May 2014 and February 2017, the Financial Accounting Standards Board (“FASB”) issued four ASUs changing the requirements for recognizing and reporting revenue (together, herein referred to as the “Revenue ASUs”): (i) ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), (ii) ASU No. 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”), (iii) ASU No. 2016-12, Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”), and (iv) ASU No. 2017-05, Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (“ASU 2017-05”). ASU 2014-09 provides guidance for revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2016-08 is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2016-12 provides practical expedients and improvements on the previously narrow scope of ASU 2014-09. ASU 2017-05 clarifies the scope of the FASB’s recently established guidance on nonfinancial asset derecognition and aligns the accounting for partial sales of nonfinancial assets and in-substance nonfinancial assets with the guidance in ASU 2014-09. The Company adopted the Revenue ASUs effective January 1, 2018 and utilized a modified retrospective adoption approach, resulting in a cumulative-effect adjustment to equity of $79 million as of January 1, 2018. Under the Revenue ASUs, the Company also elected to utilize a practical expedient which allows the Company to only reassess contracts that were not completed as of the adoption date, rather than all historical contracts. As the primary source of revenue for the Company is generated through leasing arrangements, for which timing and recognition of revenue are excluded from the Revenue ASUs, the impact of the Revenue ASUs, upon and subsequent to adoption, is generally limited to the following: • The Company, along with its JV partners and independent SHOP operators, provide certain ancillary services to SHOP residents that are not contemplated in the lease with each resident (i.e., guest meals, concierge services, pharmacy services, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. The Company records ancillary service revenue within resident fees and services and, under the Revenue ASUs, is required to disclose, on an ongoing basis, ancillary service revenue generated from its RIDEA structures. Included within resident fees and services for the quarters ended March 31, 2018 and 2017 is $10 million of ancillary service revenue. • Prior to the adoption of the Revenue ASUs, the Company recognized a gain on sale of real estate using the full accrual method when collectibility of the sales price was reasonably assured, the Company was not obligated to perform additional activities that may be considered significant, the initial investment from the buyer was sufficient and other profit recognition criteria had been satisfied. The Company deferred all or a portion of a gain on sale of real estate if the requirements for gain recognition were not met at the time of sale. Subsequent to adopting the Revenue ASUs on January 1, 2018, the Company began recognizing a gain on sale of real estate upon transferring control of the asset to the purchaser, which is generally satisfied at the time of sale. In conjunction with its adoption of the Revenue ASUs, the Company reassessed its historical partial sale of real estate transactions to determine which transactions, if any, were not completed contracts (i.e., the transaction did not qualify for sale treatment under previous guidance). The Company concluded that it had one such material transaction, its partial sale of RIDEA II in the first quarter of 2017 (which was not a completed sale under historical guidance as of the Company's adoption date due to a minor obligation related to the interest sold). In accordance with the Revenue ASUs, the Company recorded its retained 40% equity investment at fair value as of the sale date. As a result, the Company recorded an adjustment to equity as of January 1, 2018 (under the modified retrospective transition approach) representing a step-up in the fair value of its equity investment in RIDEA II of $107 million (to a carrying value of $121 million as of January 1, 2018) and a $30 million impairment charge to decrease the carrying value to the expected sales price of the investment (see Note 4). • The Company generally expects that the new guidance will result in certain transactions qualifying as sales of real estate at an earlier date than under historical accounting guidance. The following table illustrates changes in the Company’s consolidated balance sheet as reported and as it would have been reported prior to the adoption of the Revenue ASUs as of March 31, 2018 (in thousands): March 31, 2018 As Reported As Would Have Been Reported Prior to Adoption Investments in and advances to unconsolidated joint ventures 863,775 792,291 Other assets, net 583,261 586,066 Deferred revenue 167,975 178,440 Total stockholders' equity 5,206,291 5,127,147 Additionally, effective January 1, 2018, the Company adopted the following ASUs, each of which did not have a material impact to its consolidated financial position, results of operations, cash flows or disclosures upon adoption: • ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”) and ASU No. 2018-03, Technical Corrections and Improvements to Financial Instruments - Overall (“ASU 2018-03”). The core principle of the amendments in ASU 2016-01 and ASU 2018-03 involves the measurement of equity investments (except those accounted for under the equity method of accounting or those that result in consolidation) at fair value and the recognition of changes in fair value of those investments during each reporting period in net income (loss). As a result, ASU 2016-01 and ASU 2018-03 eliminate the cost method of accounting for equity securities that do not have readily determinable fair values. Pursuant to the new guidance, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. • ASU No. 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”). The amendments in ASU 2016-16 require an entity to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time that the transfer occurs. Historical guidance does not require recognition of tax consequences until the asset is eventually sold to a third party. During the fourth quarter of 2017, the Company adopted ASU No. 2016-18, Restricted Cash (“ASU 2016-18”) and ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”) (collectively, the “Cash Flow ASUs”). ASU 2016-18 requires an entity to reconcile and explain the period-over-period change in total cash, cash equivalents and restricted cash within its statements of cash flows and ASU 2016-15 provides guidance clarifying how certain cash receipts and cash payments should be classified. The full retrospective approach of adoption is required for the Cash Flow ASUs and, accordingly, certain line items in the Company’s consolidated statements of cash flows have been reclassified to conform to the current period presentation. The following table illustrates changes in the Company’s cash flows as reported and as previously reported prior to the adoption of the Cash Flow ASUs during the fourth quarter of 2017 (in thousands): Three Months Ended March 31, 2017 As Reported As Previously Reported Net cash provided by (used in) investing activities $ 1,733,763 $ 1,715,217 Net increase (decrease) in balance (1) 687,930 669,384 Balance - beginning of period (1) 136,990 94,730 Balance - end of period (1) 824,920 764,114 _______________________________________ (1) Amounts in the As Reported column include cash and cash equivalents and restricted cash as required upon the adoption of the Cash Flow ASUs. Amounts in the As Previously Reported column reflect only cash and cash equivalents. In addition to the changes in the consolidated statements of cash flows as a result of the adoption the Cash Flow ASUs, certain amounts within the consolidated statements of cash flows have been reclassified for prior periods to conform to the current period presentation. Such reclassifications primarily combined line items of similar classes of transactions and had no impact on the cash flows from operating, investing and financing activities. Leases. In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the current accounting for leases to: (i) require lessees to put most leases on their balance sheets, but continue recognizing expenses on their income statements in a manner similar to requirements under current accounting guidance, (ii) eliminate current real estate specific lease provisions, and (iii) modify the classification criteria and accounting for sales-type leases for lessors. ASU 2016-02 is effective for fiscal years, and interim periods within, beginning after December 15, 2018. Early adoption is permitted. The transition method required by ASU 2016-02 varies based on the specific amendment being adopted. As a result of adopting ASU 2016-02, the Company: (i) will recognize all of its significant operating leases for which it is the lessee, including corporate office leases, equipment leases, and ground leases, on its consolidated balance sheets, (ii) will capitalize fewer legal costs related to the drafting and execution of its lease agreements, and (iii) may be required to increase its revenue and expense for the amount of real estate taxes and insurance paid by its tenants under triple-net leases. ASU 2016-02 provides a practical expedient, which the Company plans to elect, that allows an entity to not reassess the following upon adoption (must be elected as a group): (i) whether an expired or existing contract contains a lease arrangement, (ii) lease classification related to expired or existing lease arrangements, or (iii) whether costs incurred on expired or existing leases qualify as initial direct costs. Although not yet finalized, the FASB has also proposed an option for lessors to elect a practical expedient allowing them to not separate lease and nonlease components in a contract for the purpose of revenue recognition and disclosure. This practical expedient is limited to circumstances in which (i) the timing and pattern of transfer are the same for the nonlease component and the related lease component and (ii) the lease component would be classified as an operating lease. If finalized, the Company plans to elect this practical expedient as well. The Company is still evaluating the complete impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial position, results of operations and disclosures. Credit Losses. In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments held by financial institutions and other organizations. The amendments in ASU 2016-13 eliminate the “probable” initial threshold for recognition of credit losses in current accounting guidance and, instead, reflect an entity’s current estimate of all expected credit losses over the life of the financial instrument. Previously, when credit losses were measured under current accounting guidance, an entity generally only considered past events and current conditions in measuring the incurred loss. The amendments in ASU 2016-13 broaden the information that an entity must consider in developing its expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. ASU 2016-13 is effective for fiscal years, and interim periods within, beginning after December 15, 2019. Early adoption is permitted for fiscal years, and interim periods within, beginning after December 15, 2018. A reporting entity is required to apply the amendments in ASU 2016-13 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Upon adoption of ASU 2016-13, the Company is required to reassess its financing receivables, including direct financing leases (“DFLs”) and loans receivable, and expects that application of ASU 2016-13 may result in the Company recognizing credit losses at an earlier date than would otherwise be recognized under current accounting guidance. The Company is evaluating the impact of the adoption of ASU 2016-13 on January 1, 2020 to its consolidated financial position and results of operations. The following ASU has been issued, but not adopted, and the Company does not expect a material impact to its consolidated financial position, results of operations, cash flows, or disclosures upon adoption: • ASU No. 2017-12, Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”). ASU 2017-12 is effective for fiscal years, including interim periods within, beginning after December 15, 2018 and early adoption is permitted. The amendments in ASU 2017-12 expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. For cash flow and net investment hedges existing at the date of adoption, a reporting entity must apply the amendments in ASU 2017-12 using the modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. The presentation and disclosure amendments in ASU 2017-12 must be applied using a prospective approach. |
Summary of Significant Accoun28
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Accounting Policies [Abstract] | |
Schedule of Impact on Financial Statements from Adopting New Accounting Guidance | The following table illustrates changes in the Company’s cash flows as reported and as previously reported prior to the adoption of the Cash Flow ASUs during the fourth quarter of 2017 (in thousands): Three Months Ended March 31, 2017 As Reported As Previously Reported Net cash provided by (used in) investing activities $ 1,733,763 $ 1,715,217 Net increase (decrease) in balance (1) 687,930 669,384 Balance - beginning of period (1) 136,990 94,730 Balance - end of period (1) 824,920 764,114 _______________________________________ (1) Amounts in the As Reported column include cash and cash equivalents and restricted cash as required upon the adoption of the Cash Flow ASUs. Amounts in the As Previously Reported column reflect only cash and cash equivalents. The following table illustrates changes in the Company’s consolidated balance sheet as reported and as it would have been reported prior to the adoption of the Revenue ASUs as of March 31, 2018 (in thousands): March 31, 2018 As Reported As Would Have Been Reported Prior to Adoption Investments in and advances to unconsolidated joint ventures 863,775 792,291 Other assets, net 583,261 586,066 Deferred revenue 167,975 178,440 Total stockholders' equity 5,206,291 5,127,147 |
Net Investment in Direct Fina29
Net Investment in Direct Financing Leases (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Leases, Capital [Abstract] | |
Schedule of Components of Net Investment in DFLs | Net investment in DFLs consisted of the following (dollars in thousands): March 31, December 31, Minimum lease payments receivable $ 1,049,400 $ 1,062,452 Estimated residual value 504,457 504,457 Less unearned income (840,394 ) (852,557 ) Net investment in direct financing leases $ 713,463 $ 714,352 Properties subject to direct financing leases 29 29 |
Summary of the Company's Internal Ratings for DFLs | The following table summarizes the Company’s internal ratings for DFLs at March 31, 2018 (dollars in thousands): Carrying Amount Percentage of DFL Portfolio Internal Ratings Segment Performing DFLs Watch List DFLs Workout DFLs Senior housing triple-net $ 628,859 88 $ 274,264 $ 354,595 $ — Other non-reportable segments 84,604 12 84,604 — — $ 713,463 100 $ 358,868 $ 354,595 $ — The following table summarizes the Company’s internal ratings for loans receivable at March 31, 2018 (dollars in thousands): Carrying Amount Percentage of Loan Portfolio Internal Ratings Investment Type Performing Loans Watch List Loans Workout Loans Real estate secured $ 24,990 53 $ 24,990 $ — $ — Other secured 22,022 47 22,022 — — $ 47,012 100 $ 47,012 $ — $ — |
Loans Receivable (Tables)
Loans Receivable (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Receivables [Abstract] | |
Schedule of Loans Receivable | The following table summarizes the Company’s loans receivable (in thousands): March 31, 2018 December 31, 2017 Real Estate Secured Other Secured Total Real Estate Secured Other Secured Total Mezzanine (1) $ — $ 22,105 $ 22,105 $ — $ 269,299 $ 269,299 Other (2) 24,990 — 24,990 188,418 — 188,418 Unamortized discounts, fees and costs — (83 ) (83 ) — (596 ) (596 ) Allowance for loan losses (3) — — — — (143,795 ) (143,795 ) $ 24,990 $ 22,022 $ 47,012 $ 188,418 $ 124,908 $ 313,326 _______________________________________ (1) In December 2017, the Company entered into a participating debt financing arrangement to fund a $115 million senior living development project, which remained unfunded at March 31, 2018 . (2) Represents loans denominated in British pound sterling (“GBP”). At December 31, 2017 , includes the U.K. Bridge Loan discussed below. (3) Related to the Company’s mezzanine loan facility to Tandem Health Care discussed below. |
Summary of the Company's Internal Ratings for Loans Receivable | The following table summarizes the Company’s internal ratings for DFLs at March 31, 2018 (dollars in thousands): Carrying Amount Percentage of DFL Portfolio Internal Ratings Segment Performing DFLs Watch List DFLs Workout DFLs Senior housing triple-net $ 628,859 88 $ 274,264 $ 354,595 $ — Other non-reportable segments 84,604 12 84,604 — — $ 713,463 100 $ 358,868 $ 354,595 $ — The following table summarizes the Company’s internal ratings for loans receivable at March 31, 2018 (dollars in thousands): Carrying Amount Percentage of Loan Portfolio Internal Ratings Investment Type Performing Loans Watch List Loans Workout Loans Real estate secured $ 24,990 53 $ 24,990 $ — $ — Other secured 22,022 47 22,022 — — $ 47,012 100 $ 47,012 $ — $ — |
Investments in and Advances t31
Investments in and Advances to Unconsolidated Joint Ventures (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Schedule of Equity Method Investments | The Company owns interests in the following entities that are accounted for under the equity method (dollars in thousands): Carrying Amount March 31, December 31, Entity (1) Ownership% 2018 2017 CCRC JV 49 $ 395,005 $ 400,241 RIDEA II (2) 40 328,873 259,651 Life Science JVs (3) 50 - 63 65,016 65,581 MBK JV 50 37,442 38,005 Development JVs (4) 50 - 90 23,733 23,365 Medical Office JVs (5) 20 - 67 12,395 12,488 K&Y JVs (6) 80 1,298 1,283 Advances to unconsolidated joint ventures, net 13 226 $ 863,775 $ 800,840 _______________________________________ (1) These entities are not consolidated because the Company does not control, through voting rights or other means, the JVs. (2) Effective January 1, 2018, the Company increased its carrying value in RIDEA II as a net adjustment to retained earnings under its elected transition approach in accordance with the adoption of ASU 2017-05 (see Note 2). See Note 4 for further information on the deconsolidation and pending sale of RIDEA II. (3) Includes the following unconsolidated partnerships (and the Company’s ownership percentage): (i) Torrey Pines Science Center, LP ( 50% ); (ii) Britannia Biotech Gateway, LP ( 55% ); and (iii) LASDK, LP ( 63% ). (4) Includes four unconsolidated SHOP development partnerships (and the Company’s ownership percentage): (i) Vintage Park Development JV ( 85% ); (ii) Waldwick JV ( 85% ); (iii) Otay Ranch JV ( 90% ); and (iv) MBK Development JV ( 50% ). (5) Includes three unconsolidated medical office partnerships (and the Company’s ownership percentage): HCP Ventures IV, LLC ( 20% ); HCP Ventures III, LLC ( 30% ); and Suburban Properties, LLC ( 67% ). (6) Includes three unconsolidated JVs. |
Intangibles (Tables)
Intangibles (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Intangibles | |
Schedule of Intangible Lease Assets | The following tables summarize the Company’s intangible lease assets and liabilities (in thousands): Intangible lease assets March 31, December 31, Gross intangible lease assets $ 732,110 $ 795,305 Accumulated depreciation and amortization (336,812 ) (385,223 ) Intangible assets, net $ 395,298 $ 410,082 |
Schedule of Intangible Lease Liabilities | Intangible lease liabilities March 31, December 31, Gross intangible lease liabilities $ 124,609 $ 126,212 Accumulated depreciation and amortization (72,033 ) (73,633 ) Intangible liabilities, net $ 52,576 $ 52,579 |
Debt (Tables)
Debt (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Debt Disclosure [Abstract] | |
Summary of Senior Notes Issuances | The following table summarizes the Company’s senior unsecured notes payoffs during the year ended December 31, 2017 (dollars in thousands): Date Amount Coupon Rate May 1, 2017 $ 250,000 5.625 % July 27, 2017 $ 500,000 5.375 % |
Summary of Debt Maturities and Schedule Principal Repayments | The following table summarizes the Company’s stated debt maturities and scheduled principal repayments at March 31, 2018 (in thousands): Year Bank Line of Credit (1) Term Loan (2) Senior Unsecured Notes (3) Mortgage Debt (4) Total (5) 2018 (nine months) $ — $ — $ — $ 2,649 $ 2,649 2019 — 237,175 450,000 3,700 690,875 2020 — — 800,000 3,758 803,758 2021 1,092,357 — 700,000 11,117 1,803,474 2022 — — 900,000 2,861 902,861 Thereafter — — 3,600,000 113,619 3,713,619 1,092,357 237,175 6,450,000 137,704 7,917,236 (Discounts), premium and debt costs, net — (297 ) (51,024 ) 5,820 (45,501 ) $ 1,092,357 $ 236,878 $ 6,398,976 $ 143,524 $ 7,871,735 _______________________________________ (1) Includes £105 million translated into U.S. dollars (“USD”). (2) Represents £169 million translated into USD. (3) Effective interest rates on the notes ranged from 2.79% to 6.88% with a weighted average effective interest rate of 4.20% and a weighted average maturity of six years . (4) Interest rates on the mortgage debt ranged from 1.95% to 5.91% with a weighted average effective interest rate of 4.18% and a weighted average maturity of 20 years . (5) Excludes $94 million of other debt that have no scheduled maturities. |
Equity (Tables)
Equity (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Equity [Abstract] | |
Schedule of Accumulated Other comprehensive Loss | The following table summarizes the Company’s accumulated other comprehensive income (loss) (in thousands): March 31, December 31, Cumulative foreign currency translation adjustment $ 697 $ (6,955 ) Unrealized gains (losses) on cash flow hedges, net (18,989 ) (13,950 ) Supplemental Executive Retirement plan minimum liability and other (3,015 ) (3,119 ) Total other comprehensive income (loss) $ (21,307 ) $ (24,024 ) |
Segment Disclosures (Tables)
Segment Disclosures (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Segment Reporting [Abstract] | |
Summary of Financial Information of Reportable Segments | The following tables summarize information for the reportable segments (in thousands): For the three months ended March 31, 2018 : Senior Housing Triple-Net SHOP Life Science Medical Office Other Non-reportable Corporate Non-segment Total Rental revenues (1) $ 74,289 $ 144,670 $ 99,622 $ 123,935 $ 30,316 $ — $ 472,832 Operating expenses (1,045 ) (101,746 ) (21,809 ) (46,696 ) (1,256 ) — (172,552 ) NOI 73,244 42,924 77,813 77,239 29,060 — 300,280 Adjustments to NOI (2) (1,865 ) (1,607 ) (3,751 ) (1,071 ) (1,392 ) — (9,686 ) Adjusted NOI 71,379 41,317 74,062 76,168 27,668 — 290,594 Addback adjustments 1,865 1,607 3,751 1,071 1,392 — 9,686 Interest income — — — — 6,365 — 6,365 Interest expense (600 ) (988 ) (83 ) (120 ) (728 ) (72,583 ) (75,102 ) Depreciation and amortization (21,906 ) (27,628 ) (36,080 ) (45,519 ) (12,117 ) — (143,250 ) General and administrative — — — — — (29,175 ) (29,175 ) Transaction costs — — — — — (2,195 ) (2,195 ) Gain (loss) on sales of real estate, net — 20,815 — — — — 20,815 Other income (expense), net — — — — (40,567 ) 160 (40,407 ) Income tax benefit (expense) — — — — — 5,336 5,336 Equity income (loss) from unconsolidated JVs — — — — 570 — 570 Net income (loss) $ 50,738 $ 35,123 $ 41,650 $ 31,600 $ (17,417 ) $ (98,457 ) $ 43,237 _______________________________________ (1) Represents rental and related revenues, tenant recoveries, resident fees and services, and income from DFLs. (2) Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, deferral of community fees, net and termination fees. For the three months ended March 31, 2017 : Senior Housing Triple-Net SHOP Life Science Medical Office Other Non-reportable Corporate Non-segment Total Rental revenues (1) $ 100,034 $ 140,228 $ 85,321 $ 118,371 $ 29,883 $ — $ 473,837 Operating expenses (1,111 ) (94,539 ) (17,319 ) (44,864 ) (1,248 ) — (159,081 ) NOI 98,923 45,689 68,002 73,507 28,635 — 314,756 Adjustments to NOI (2) (1,839 ) (310 ) (305 ) (961 ) (1,012 ) — (4,427 ) Adjusted NOI 97,084 45,379 67,697 72,546 27,623 — 310,329 Addback adjustments 1,839 310 305 961 1,012 — 4,427 Interest income — — — — 18,331 — 18,331 Interest expense (627 ) (4,596 ) (104 ) (129 ) (1,997 ) (79,265 ) (86,718 ) Depreciation and amortization (26,411 ) (26,358 ) (33,791 ) (42,729 ) (7,265 ) — (136,554 ) General and administrative — — — — — (22,478 ) (22,478 ) Transaction costs — — — — — (1,057 ) (1,057 ) Gain (loss) on sales of real estate, net 268,464 366 44,633 — 3,795 — 317,258 Other income (expense), net — — — — 50,895 313 51,208 Income tax benefit (expense) — — — — — 6,162 6,162 Equity income (loss) from unconsolidated JVs — — — — 3,269 — 3,269 Net income (loss) $ 340,349 $ 15,101 $ 78,740 $ 30,649 $ 95,663 $ (96,325 ) $ 464,177 _______________________________________ (1) Represents rental and related revenues, tenant recoveries, resident fees and services, and income from DFLs. (2) Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, deferral of community fees, net and termination fees. |
Reconciliation of Company's Revenues by Segment | The following table summarizes the Company’s revenues by segment (in thousands): Three Months Ended March 31, Segment 2018 2017 Senior housing triple-net $ 74,289 $ 100,034 SHOP 144,670 140,228 Life science 99,622 85,321 Medical office 123,935 118,371 Other non-reportable segments 36,681 48,214 Total revenues $ 479,197 $ 492,168 |
Earnings Per Common Share (Tabl
Earnings Per Common Share (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Earnings Per Share [Abstract] | |
Computation of Basic and Diluted Earnings per Share | The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts): Three Months Ended 2018 2017 Numerator Net income (loss) from continuing operations $ 43,237 $ 464,177 Noncontrolling interests' share in earnings (3,005 ) (3,032 ) Net income (loss) attributable to HCP, Inc. 40,232 461,145 Less: Participating securities' share in earnings (391 ) (770 ) Net income (loss) applicable to common shares $ 39,841 $ 460,375 Numerator - Dilutive Net income (loss) applicable to common shares $ 39,841 $ 460,375 Add: distributions on dilutive convertible units and other — 2,803 Dilutive net income (loss) available to common shares $ 39,841 $ 463,178 Denominator Basic weighted average shares outstanding 469,557 468,299 Dilutive potential common shares - equity awards 138 229 Dilutive potential common shares - DownREIT conversions — 6,645 Diluted weighted average common shares 469,695 475,173 Earnings per common share: Basic $ 0.08 $ 0.98 Diluted $ 0.08 $ 0.97 |
Supplemental Cash Flow Inform37
Supplemental Cash Flow Information (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Supplemental Cash Flow Elements [Abstract] | |
Supplemental Cash Flow Information | The following table provides supplemental cash flow information (in thousands): Three Months Ended March 31, 2018 2017 Supplemental cash flow information: Interest paid, net of capitalized interest $ 92,701 $ 108,232 Income taxes paid 340 1,105 Capitalized interest 3,578 3,090 Supplemental schedule of non-cash investing and financing activities: Accrued construction costs 62,160 51,498 Derecognition of U.K. Bridge Loan receivable 147,474 — Consolidation of net assets related to U.K. Bridge Loan 106,457 — Deconsolidation of noncontrolling interest in connection with RIDEA II transaction — 58,061 Vesting of restricted stock units and conversion of non-managing member units into common stock 258 1,841 |
Schedule of Cash, Cash Equivalents and Restricted Cash | The following table summarizes cash, cash equivalents and restricted cash (in thousands): March 31, 2018 2017 Cash and cash equivalents $ 86,021 $ 764,114 Restricted cash 31,947 60,806 Cash, cash equivalents and restricted cash $ 117,968 $ 824,920 |
Variable Interest Entities (Tab
Variable Interest Entities (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Variable Interest Entities [Abstract] | |
Schedule of Variable Interest Entities | The classification of the related assets and liabilities and the maximum loss exposure as a result of the Company’s involvement with these VIEs at March 31, 2018 was as follows (in thousands): VIE Type Asset/Liability Type Maximum Loss Exposure and Carrying Amount (1) VIE tenants - DFLs (2) Net investment in DFLs $ 600,822 VIE tenants - operating leases (2) Lease intangibles, net and straight-line rent receivables 5,983 CCRC OpCo Investments in unconsolidated joint ventures 190,662 RIDEA II PropCo Investments in unconsolidated joint ventures 309,882 Unconsolidated Development JVs Investments in unconsolidated joint ventures 13,070 Loan - Seller Financing Loans receivable, net 10,000 CMBS and LLC investment Marketable debt and cost method investment 33,874 _______________________________________ (1) The Company’s maximum loss exposure represents the aggregate carrying amount of such investments (including accrued interest). (2) The Company’s maximum loss exposure may be mitigated by re-leasing the underlying properties to new tenants upon an event of default. |
Consolidated Assets and Liabilities of Variable Interest Entities | Total assets and total liabilities include VIE assets and liabilities as follows (in thousands): March 31, 2018 December 31, 2017 Assets Buildings and improvements $ 1,744,402 $ 2,436,414 Development costs and construction in progress 16,226 32,285 Land 170,889 227,162 Accumulated depreciation and amortization (345,331 ) (542,091 ) Net real estate 1,586,186 2,153,770 Investments in and advances to unconsolidated joint ventures 2,148 2,231 Accounts receivable, net 7,287 10,242 Cash and cash equivalents 12,077 15,861 Restricted cash 2,595 2,619 Intangible assets, net 111,149 125,475 Other assets, net 35,788 33,749 Total assets $ 1,757,230 $ 2,343,947 Liabilities Mortgage debt 44,882 45,016 Intangible liabilities, net 12,509 10,672 Accounts payable and accrued liabilities 223,708 269,280 Deferred revenue 15,275 14,432 Total liabilities $ 296,374 $ 339,400 |
Concentration of Credit Risk (T
Concentration of Credit Risk (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Risks and Uncertainties [Abstract] | |
Schedule of Concentration of Credit Risk | The following tables provide information regarding the Company’s concentrations of credit risk with respect to certain tenants: Percentage of Total Assets Total Company Senior Housing Triple-Net March 31, December 31, March 31, December 31, Tenant 2018 2017 2018 2017 Brookdale 10 10 39 39 Percentage of Revenues Total Company Senior Housing Triple-Net Three Months Ended March 31, Three Months Ended March 31, Tenant 2018 2017 2018 2017 Brookdale (1) 7 12 43 60 _______________________________________ (1) The Company's concentration with respect to Brookdale as a tenant is expected to decrease with the completion of the Brookdale Transactions (see Note 3). Includes revenues from 64 senior housing triple-net facilities that were sold in March 2017. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Financial Instruments, Owned, at Fair Value [Abstract] | |
Summary of Carry Amounts and Fair Value of Financial Instruments | The table below summarizes the carrying amounts and fair values of the Company’s financial instruments (in thousands): March 31, 2018 (3) December 31, 2017 (3) Carrying Value Fair Value Carrying Value Fair Value Loans receivable, net (2) $ 47,012 $ 47,075 $ 313,326 $ 313,242 Marketable debt securities (2) 18,814 18,814 18,690 18,690 Bank line of credit (2) 1,092,357 1,092,357 1,017,076 1,017,076 Term loan (2) 236,878 236,878 228,288 228,288 Senior unsecured notes (1) 6,398,976 6,577,155 6,396,451 6,737,825 Mortgage debt (2) 143,524 137,704 144,486 125,984 Other debt (2) 93,856 93,856 94,165 94,165 Interest-rate swap liabilities (2) 1,931 1,931 2,483 2,483 Cross currency swap liability (2) 16,684 16,684 10,968 10,968 _______________________________________ (1) Level 1: Fair value calculated based on quoted prices in active markets. (2) Level 2: Fair value based on (i) for marketable debt securities, quoted prices for similar or identical instruments in active or inactive markets, respectively, or (ii) for loans receivable, net, mortgage debt, and swaps, calculated utilizing standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit, term loan and other debt, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company’s credit rating. (3) During the three months ended March 31, 2018 and year ended December 31, 2017 , there were no material transfers of financial assets or liabilities within the fair value hierarchy. |
Derivative Financial Instrume41
Derivative Financial Instruments (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Derivative Instruments | The following table summarizes the Company’s outstanding interest-rate and cross currency swap contracts at March 31, 2018 (dollars and GBP in thousands): Date Entered Maturity Date Hedge Designation Notional Pay Rate Receive Rate Fair Value (1) Interest rate: July 2005 (2) July 2020 Cash Flow $ 43,000 3.82% BMA Swap Index $ (1,931 ) Cross currency swap: April 2017 (3) February 2019 Net Investment £105,000 / $131,000 2.58% 3.75 % $ (16,684 ) ______________________________________ (1) Derivative assets are recorded in other assets, net and derivative liabilities are recorded in accounts payable and accrued liabilities on the consolidated balance sheets. (2) Represents three interest-rate swap contracts, which hedge fluctuations in interest payments on variable-rate secured debt due to overall changes in hedged cash flows. (3) Represents a cross currency swap to pay 2.58% on £105 million and receive 3.75% on $131 million through February 1, 2019, with an initial and final exchange of principals at origination and maturity at a rate of 1.251 USD/GBP. Hedges the risk of changes in the USD equivalent value of a portion of the Company’s net investment in its consolidated GBP subsidiaries’ attributable to changes in the USD/GBP exchange rate. |
Summary of Significant Accoun42
Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands | Jan. 01, 2018 | Mar. 31, 2018 | Mar. 31, 2017 | Dec. 31, 2017 |
Schedule of Equity Method Investments [Line Items] | ||||
Cumulative effect adjustment to equity | $ 5,206,291 | $ 5,301,005 | ||
Resident fees and services | $ 142,814 | $ 140,232 | ||
RIDEA II | ||||
Schedule of Equity Method Investments [Line Items] | ||||
Investment ownership percentage | 40.00% | 40.00% | ||
Equity method investments | $ 121,000 | |||
Difference between Revenue Guidance in Effect before and after Topic 606 | ASU 2014-09 | ||||
Schedule of Equity Method Investments [Line Items] | ||||
Cumulative effect adjustment to equity | 79,000 | |||
Impairment charge | 30,000 | |||
Difference between Revenue Guidance in Effect before and after Topic 606 | ASU 2014-09 | RIDEA II | ||||
Schedule of Equity Method Investments [Line Items] | ||||
Fair value of equity method investments | $ 107,000 | |||
Ancillary service revenue | ASU 2014-09 | ||||
Schedule of Equity Method Investments [Line Items] | ||||
Resident fees and services | $ 10,000 | $ 10,000 |
Summary of Significant Accoun43
Summary of Significant Accounting Policies - Schedule of Balance Sheets Impact from ASUs Adoption (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Investments in and advances to unconsolidated joint ventures | $ 863,775 | $ 800,840 |
Other assets, net | 583,261 | 578,033 |
Deferred revenue | 167,975 | 144,709 |
Total stockholders' equity | 5,206,291 | $ 5,301,005 |
As Would Have Been Reported Prior to Adoption | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Investments in and advances to unconsolidated joint ventures | 792,291 | |
Other assets, net | 586,066 | |
Deferred revenue | 178,440 | |
Total stockholders' equity | $ 5,127,147 |
Summary of Significant Accoun44
Summary of Significant Accounting Policies - Schedule of Cash Flows Impact from ASUs Adoption (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Net cash provided by (used in) investing activities | $ 10,728 | $ 1,733,763 |
Net increase (decrease) in balance | 35,765 | 687,930 |
Cash, cash equivalents and restricted cash, beginning of period | 82,203 | 136,990 |
Cash, cash equivalents and restricted cash, end of period | 117,968 | 824,920 |
Balance - of continuing operations end of year | $ 117,968 | 824,920 |
As Previously Reported | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Net cash provided by (used in) investing activities | 1,715,217 | |
Net increase (decrease) in balance | 669,384 | |
Cash, cash equivalents and restricted cash, beginning of period | 94,730 | |
Cash, cash equivalents and restricted cash, end of period | 764,114 | |
Balance - of continuing operations end of year | $ 764,114 |
Master Transactions and Coope45
Master Transactions and Cooperation Agreement with Brookdale (Details) $ in Millions | Nov. 01, 2017USD ($)propertyagreement | Apr. 30, 2018USD ($)propertyfacility | Mar. 31, 2018USD ($) | Jan. 31, 2018USD ($)propertyfacility | Dec. 31, 2017USD ($) | Mar. 31, 2017USD ($)property | Mar. 31, 2018property | Jan. 01, 2018USD ($)property |
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Percentage of interest acquired | 10.00% | |||||||
Consideration transferred | $ | $ 95 | |||||||
Payment to acquired noncontrolling interest | $ | $ 63 | $ 32 | ||||||
CCRC JV | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Investment ownership percentage | 49.00% | 49.00% | ||||||
RIDEA Facilities | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Ownership percentage (as a percent) | 90.00% | |||||||
Assets Leased to Others | RIDEA Facilities | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Number of properties | 58 | |||||||
Assets Leased to Others | Brookdale | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Number of properties | 78 | |||||||
Senior housing triple-net | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Number of properties sold | 64 | |||||||
Total consideration for disposal of real estate | $ | $ 1,125 | |||||||
Senior housing triple-net | Subsequent Event | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Number of properties sold | facility | 2 | |||||||
Senior housing triple-net | Assets Leased to Others | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Number of properties | 34 | |||||||
Properties with right to sell or transition to other operator | 32 | |||||||
Right to sell and transfer period for operating leases | 1 year | |||||||
Properties transitioned to cash flow leases expiration period | 2 years | |||||||
Amount of annual rent cut | $ | $ 5 | |||||||
Number of assets with annual rent cut | 3 | |||||||
Senior housing triple-net | Assets Leased to Others | Subsequent Event | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Number of properties sold | 2 | |||||||
Total consideration for disposal of real estate | $ | $ 35 | |||||||
SHOP | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Number of properties sold | facility | 2 | |||||||
Total consideration for disposal of real estate | $ | $ 35 | |||||||
SHOP | CCRC JV | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Investment ownership percentage | 49.00% | 49.00% | ||||||
Ownership interest held by Parent | 51.00% | 51.00% | ||||||
SHOP | Subsequent Event | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Number of properties sold | facility | 4 | |||||||
SHOP | Assets Leased to Others | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Number of assets transitioned out | 8 | |||||||
SHOP | Assets Leased to Others | RIDEA Facilities | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Number of properties | 36 | |||||||
Management termination period | 1 year | |||||||
Number of properties sold | 1 | |||||||
Base management fee, percentage of gross revenue | 5.00% | |||||||
Percentage of annual increase in management fee | 1.00% | |||||||
Management fee annual rent increase period | 2 years | |||||||
Number of assets to be sold | 4 | |||||||
Total consideration for disposition of real estate | $ | $ 239 | |||||||
Proceeds from sale of productive assets | $ | $ 32 | |||||||
Number of assets under management agreement | 18 | |||||||
Number of management agreement with termination rights | agreement | 7 | |||||||
Management agreements with termination rights period | 10 years | |||||||
SHOP | Assets Leased to Others | RIDEA Facilities | Subsequent Event | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Number of properties sold | 3 | |||||||
Proceeds from sale of productive assets | $ | $ 207 | |||||||
SHOP | Assets Leased to Others | RIDEA Facilities | Maximum | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Base management fee, percentage of gross revenue | 7.00% | |||||||
SHOP | Assets Leased to Others | Separate RIDEA structure | ||||||||
Lease Amendments And Terminations And Joint Venture Formations. | ||||||||
Number of assets under management agreement | 2 |
Real Estate Transactions - Held
Real Estate Transactions - Held for Sale (Details) $ in Thousands | Mar. 31, 2018USD ($)property | Dec. 31, 2017USD ($)property |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Assets held for sale, net | $ 436,155 | $ 417,014 |
Accumulated depreciation | 2,826,325 | 2,741,695 |
Held-for-sale | ||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Assets held for sale, net | $ 436,000 | $ 417,000 |
Held-for-sale | SHOP | ||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Number of properties classified as held for sale | property | 7 | 6 |
Held-for-sale | Senior housing triple-net | ||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Number of properties classified as held for sale | property | 2 | 2 |
Held-for-sale | Life science | ||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Number of properties classified as held for sale | property | 4 | 4 |
Held-for-sale | Real Estate | ||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Assets held for sale, net | $ 410,000 | $ 393,000 |
Accumulated depreciation | $ 98,000 | $ 93,000 |
Real Estate Transactions - RIDE
Real Estate Transactions - RIDEA II Sale Transaction (Details) - USD ($) $ in Thousands | Nov. 01, 2017 | Jan. 31, 2017 | Jun. 30, 2018 | Mar. 31, 2018 | Mar. 31, 2017 |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Gain (loss) on sales of real estate | $ 20,815 | $ 317,258 | |||
HCP/CPA/Brookdale JV | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Debt Instrument Provided | $ 602,000 | ||||
Debt provided by third-party | 360,000 | ||||
Debt provided by entity | 242,000 | ||||
Net proceeds from the RIDEA II transaction | $ 480,000 | ||||
RIDEA II | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Investment ownership percentage | 40.00% | 40.00% | |||
RIDEA II | HCP/CPA/Brookdale JV | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Investment ownership percentage | 40.00% | ||||
Disposed of by Sale | RIDEA II | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Gain (loss) on sales of real estate | $ 99,000 | ||||
RIDEA II | HCP/CPA/Brookdale JV | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Debt provided by entity | $ 242,000 | ||||
Note receivable payment period | 1 year | ||||
RIDEA II | HCP/CPA/Brookdale JV | Forecast | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Equity method investment ownership interest disposed | 40.00% | ||||
Consideration of disposal of equity method investment | $ 91,000 |
Real Estate Transactions - U.K.
Real Estate Transactions - U.K. Portfolio (Details) $ in Thousands, £ in Millions | 3 Months Ended | ||
Jun. 30, 2018GBP (£) | Mar. 31, 2018USD ($) | Dec. 31, 2017USD ($) | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Value of U.K. Portfolio | $ | $ 14,067,571 | $ 14,088,461 | |
Forecast | Disposed of by Sale | U.K. Portfolio | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Ownership interest percentage selling | 51.00% | ||
Value of U.K. Portfolio | £ | £ 394 | ||
U.K. Portfolio | Forecast | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Percentage of noncontrolling interest in the joint venture | 49.00% |
Real Estate Transactions - Disp
Real Estate Transactions - Disposition of Real Estate (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | ||||
Apr. 30, 2018USD ($)facility | Jan. 31, 2018USD ($)facility | Mar. 31, 2017USD ($)property | Jan. 31, 2017USD ($)facility | Mar. 31, 2018USD ($) | Mar. 31, 2017USD ($) | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||
Gain (loss) on sales of real estate, net | $ 20,815 | $ 317,258 | ||||
SHOP | ||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||
Number of properties disposed | facility | 2 | |||||
Total consideration for disposal of real estate | $ 35,000 | |||||
Gain (loss) on sales of real estate, net | $ 21,000 | |||||
SHOP | Subsequent Event | ||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||
Number of properties disposed | facility | 4 | |||||
Senior housing triple-net | ||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||
Number of properties disposed | property | 64 | |||||
Total consideration for disposal of real estate | $ 1,125,000 | |||||
Gain (loss) on sales of real estate, net | $ 170,000 | |||||
Senior housing triple-net | Subsequent Event | ||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||
Number of properties disposed | facility | 2 | |||||
Triple-net and SHOP | Subsequent Event | ||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||
Total consideration for disposal of real estate | $ 265,000 | |||||
Life science | ||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||
Number of properties disposed | facility | 4 | |||||
Total consideration for disposal of real estate | $ 76,000 | |||||
Gain (loss) on sales of real estate, net | $ 45,000 |
Real Estate Transactions - Inve
Real Estate Transactions - Investments in Real Estate (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Real Estate [Abstract] | ||
Payments to acquire real estate | $ 21,000,000 | $ 0 |
Net Investment in Direct Fina51
Net Investment in Direct Financing Leases - Direct Financing Leases (Details) $ in Thousands | 1 Months Ended | ||
Feb. 28, 2017USD ($)property | Mar. 31, 2018USD ($)property | Dec. 31, 2017USD ($)property | |
Capital Leased Assets [Line Items] | |||
Minimum lease payments receivable | $ 1,049,400 | $ 1,062,452 | |
Estimated residual value | 504,457 | 504,457 | |
Less unearned income | (840,394) | (852,557) | |
Net investment in direct financing leases | $ 713,463 | $ 714,352 | |
Properties subject to direct financing leases | property | 29 | 29 | |
Florida | |||
Capital Leased Assets [Line Items] | |||
Number of properties sold | property | 1 | ||
Proceeds from sale of leased assets | $ 43,000 | ||
Gain on sale of a property within a direct financing lease | $ 4,000 |
Net Investment in Direct Fina52
Net Investment in Direct Financing Leases - Direct Financing Lease Internal Ratings (Details) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2018USD ($)property | Mar. 31, 2017USD ($) | Dec. 31, 2017USD ($)property | |
Net Investment in Direct Financing Leases | |||
Net investment in direct financing leases | $ 713,463 | $ 714,352 | |
Percentage of DFL Portfolio | 100.00% | ||
Properties subject to direct financing leases | property | 29 | 29 | |
DFL income | $ 13,266 | $ 13,712 | |
Performing Loans | |||
Net Investment in Direct Financing Leases | |||
Net investment in direct financing leases | 358,868 | ||
Watch List DFLs | |||
Net Investment in Direct Financing Leases | |||
Net investment in direct financing leases | 354,595 | ||
Watch List DFLs | DFL Portfolio | |||
Net Investment in Direct Financing Leases | |||
DFL income | 3,000 | 3,000 | |
Cash payments received | 5,000 | $ 4,000 | |
Workout DFLs | |||
Net Investment in Direct Financing Leases | |||
Net investment in direct financing leases | 0 | ||
Senior housing triple-net | |||
Net Investment in Direct Financing Leases | |||
Net investment in direct financing leases | $ 628,859 | ||
Percentage of DFL Portfolio | 88.00% | ||
Senior housing triple-net | Performing Loans | |||
Net Investment in Direct Financing Leases | |||
Net investment in direct financing leases | $ 274,264 | ||
Senior housing triple-net | Watch List DFLs | |||
Net Investment in Direct Financing Leases | |||
Net investment in direct financing leases | 354,595 | ||
Senior housing triple-net | Watch List DFLs | DFL Portfolio | |||
Net Investment in Direct Financing Leases | |||
Net investment in direct financing leases | $ 355,000 | $ 356,000 | |
Properties subject to direct financing leases | property | 14 | ||
Senior housing triple-net | Workout DFLs | |||
Net Investment in Direct Financing Leases | |||
Net investment in direct financing leases | $ 0 | ||
Other non-reportable segments | |||
Net Investment in Direct Financing Leases | |||
Net investment in direct financing leases | $ 84,604 | ||
Percentage of DFL Portfolio | 12.00% | ||
Other non-reportable segments | Performing Loans | |||
Net Investment in Direct Financing Leases | |||
Net investment in direct financing leases | $ 84,604 | ||
Other non-reportable segments | Watch List DFLs | |||
Net Investment in Direct Financing Leases | |||
Net investment in direct financing leases | 0 | ||
Other non-reportable segments | Workout DFLs | |||
Net Investment in Direct Financing Leases | |||
Net investment in direct financing leases | $ 0 |
Loans Receivable - Schedule of
Loans Receivable - Schedule of Loans Receivable (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2017 | Mar. 31, 2018 | |
Loans Receivable: | ||
Mezzanine | $ 269,299 | $ 22,105 |
Loans receivable, other | 188,418 | 24,990 |
Unamortized discounts, fees and costs | (596) | (83) |
Allowance for loan losses | (143,795) | 0 |
Loans receivable, net | 313,326 | 47,012 |
Loans receivable commitments | 115,000 | |
Real Estate Secured | ||
Loans Receivable: | ||
Mezzanine | 0 | 0 |
Loans receivable, other | 188,418 | 24,990 |
Unamortized discounts, fees and costs | 0 | 0 |
Allowance for loan losses | 0 | 0 |
Loans receivable, net | 188,418 | 24,990 |
Other Secured | ||
Loans Receivable: | ||
Mezzanine | 269,299 | 22,105 |
Loans receivable, other | 0 | 0 |
Unamortized discounts, fees and costs | (596) | (83) |
Allowance for loan losses | (143,795) | 0 |
Loans receivable, net | $ 124,908 | $ 22,022 |
Loans Receivable - Schedule o54
Loans Receivable - Schedule of Loans Receivable Internal Ratings (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Financing Receivable, Recorded Investment [Line Items] | ||
Percentage of Loan Portfolio | 100.00% | |
Loans receivable, net | $ 47,012 | $ 313,326 |
Performing Loans | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Loans receivable, net | 47,012 | |
Watch List Loans | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Loans receivable, net | 0 | |
Workout Loans | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Loans receivable, net | $ 0 | |
Real Estate Secured | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Percentage of Loan Portfolio | 53.00% | |
Loans receivable, net | $ 24,990 | 188,418 |
Real Estate Secured | Performing Loans | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Loans receivable, net | 24,990 | |
Real Estate Secured | Watch List Loans | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Loans receivable, net | 0 | |
Real Estate Secured | Workout Loans | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Loans receivable, net | $ 0 | |
Other Secured | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Percentage of Loan Portfolio | 47.00% | |
Loans receivable, net | $ 22,022 | $ 124,908 |
Other Secured | Performing Loans | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Loans receivable, net | 22,022 | |
Other Secured | Watch List Loans | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Loans receivable, net | 0 | |
Other Secured | Workout Loans | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Loans receivable, net | $ 0 |
Loans Receivable - Narrative (D
Loans Receivable - Narrative (Details) £ in Millions | Jun. 30, 2017USD ($) | Jun. 30, 2017GBP (£) | Mar. 31, 2018USD ($) | Mar. 31, 2017USD ($) | Mar. 31, 2017GBP (£) | Mar. 31, 2018USD ($)property | Mar. 31, 2018GBP (£)property | Mar. 31, 2017USD ($) | Dec. 31, 2017USD ($) | Dec. 31, 2016USD ($)property | Feb. 28, 2017USD ($) | Feb. 28, 2017GBP (£) | Dec. 31, 2016GBP (£)property | May 31, 2015USD ($) |
Loans Receivable: | ||||||||||||||
Loans receivable, other | $ 24,990,000 | $ 24,990,000 | $ 188,418,000 | |||||||||||
Loans receivable, net | 47,012,000 | 47,012,000 | 313,326,000 | |||||||||||
Notes reduction due to call option exercised | 147,474,000 | $ 0 | ||||||||||||
Loss from initial consolidation of VIE | 41,017,000 | 0 | ||||||||||||
MMCG | ||||||||||||||
Loans Receivable: | ||||||||||||||
Loss from initial consolidation of VIE | 41,000,000 | £ 29 | ||||||||||||
HC-One Facility | ||||||||||||||
Loans Receivable: | ||||||||||||||
Cash payments received from borrower | $ 367,000,000 | £ 283 | ||||||||||||
Tandem Mezzanine Loan | ||||||||||||||
Loans Receivable: | ||||||||||||||
Proceeds from sale of loans receivable | 112,000,000 | |||||||||||||
Cash payments received from borrower | $ 0 | $ 7,000,000 | ||||||||||||
Loans receivable, other | 105,000,000 | |||||||||||||
Impairment charges on receivable | $ 144,000,000 | |||||||||||||
Impairment recovery on receivable | $ 3,000,000 | |||||||||||||
Tandem Mezzanine Loan | Maximum | ||||||||||||||
Loans Receivable: | ||||||||||||||
Loans receivable, other | $ 257,000,000 | |||||||||||||
Bridge Loan | MMCG | ||||||||||||||
Loans Receivable: | ||||||||||||||
Loans receivable, net | $ 131,000,000 | £ 105 | ||||||||||||
Period of call-option retained | 3 years | |||||||||||||
Number of properties in a purchase option | property | 7 | 7 | ||||||||||||
Number of properties acquired in a purchase option | property | 7 | 7 | ||||||||||||
Notes reduction due to call option exercised | £ | £ 105 | |||||||||||||
Loss from initial consolidation of VIE | $ 41,000,000 | £ 29 | ||||||||||||
Four Seasons | ||||||||||||||
Loans Receivable: | ||||||||||||||
Proceeds from sale of loans receivable | $ 35,000,000 | £ 29 | ||||||||||||
Investment in held to maturity at amortized cost | £ | 138.5 | |||||||||||||
Proceeds from sale of held to maturity securities | 101,000,000 | 83 | ||||||||||||
Gain on sale of securities | $ 51,000,000 | £ 42 | ||||||||||||
Marketable debt securities, net | $ 50,000,000 | £ 41 |
Investments in and Advances t56
Investments in and Advances to Unconsolidated Joint Ventures - Schedule of Equity Method Investments (Details) $ in Thousands | Mar. 31, 2018USD ($)joint_venture | Dec. 31, 2017USD ($) | Mar. 31, 2017 |
Schedule of Equity Method Investments [Line Items] | |||
Investments in and advances to unconsolidated joint ventures | $ 863,775 | $ 800,840 | |
CCRC JV | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 49.00% | ||
Investments in and advances to unconsolidated joint ventures | $ 395,005 | 400,241 | |
RIDEA II | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 40.00% | 40.00% | |
Investments in and advances to unconsolidated joint ventures | $ 328,873 | 259,651 | |
Life Science JVs | |||
Schedule of Equity Method Investments [Line Items] | |||
Investments in and advances to unconsolidated joint ventures | $ 65,016 | 65,581 | |
Life Science JVs | Minimum | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 50.00% | ||
Life Science JVs | Maximum | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 63.00% | ||
Torrey Pines Science Center, LP | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 50.00% | ||
Britannia Biotech Gateway, LP | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 55.00% | ||
LASDK, LP | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 63.00% | ||
MBK JV | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 50.00% | ||
Investments in and advances to unconsolidated joint ventures | $ 37,442 | 38,005 | |
Development JVs | |||
Schedule of Equity Method Investments [Line Items] | |||
Investments in and advances to unconsolidated joint ventures | $ 23,733 | 23,365 | |
Number of unconsolidated joint ventures | joint_venture | 4 | ||
Development JVs | Minimum | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 50.00% | ||
Development JVs | Maximum | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 90.00% | ||
Vintage Park Development JV | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 85.00% | ||
Waldwick | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 85.00% | ||
Otay Ranch | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 90.00% | ||
MBK Development JV | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 50.00% | ||
Medical Office JVs | |||
Schedule of Equity Method Investments [Line Items] | |||
Investments in and advances to unconsolidated joint ventures | $ 12,395 | 12,488 | |
Number of unconsolidated joint ventures | joint_venture | 3 | ||
Medical Office JVs | Minimum | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 20.00% | ||
Medical Office JVs | Maximum | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 67.00% | ||
HCP Ventures VI, LLC | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 20.00% | ||
HCP Ventures III, LLC | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 30.00% | ||
Suburban Properties, LLC | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 67.00% | ||
K&Y JVs | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment ownership percentage | 80.00% | ||
Investments in and advances to unconsolidated joint ventures | $ 1,298 | 1,283 | |
Advances to unconsolidated joint ventures, net | |||
Schedule of Equity Method Investments [Line Items] | |||
Investments in and advances to unconsolidated joint ventures | $ 13 | $ 226 |
Intangibles - Intangibles Lease
Intangibles - Intangibles Lease Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Intangibles | ||
Gross intangible lease assets | $ 732,110 | $ 795,305 |
Accumulated depreciation and amortization | (336,812) | (385,223) |
Intangible assets, net | $ 395,298 | $ 410,082 |
Intangibles - Intangibles Lea58
Intangibles - Intangibles Lease Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Intangibles | ||
Gross intangible lease liabilities | $ 124,609 | $ 126,212 |
Accumulated depreciation and amortization | (72,033) | (73,633) |
Intangible liabilities, net | $ 52,576 | $ 52,579 |
Debt - Bank Line of Credit and
Debt - Bank Line of Credit and Term Loan (Details) £ in Millions | Apr. 06, 2018USD ($) | Mar. 31, 2018USD ($)renewal_option | Mar. 31, 2017USD ($) | Mar. 31, 2018GBP (£)renewal_option | Dec. 31, 2017USD ($) |
Debt Instrument | |||||
Bank line of credit | $ 1,092,357,000 | $ 1,017,076,000 | |||
Repayment under bank line of credit | 170,000,000 | $ 37,032,000 | |||
Debt | 7,871,735,000 | ||||
Outstanding balance on term loan | $ 236,878,000 | $ 228,288,000 | |||
Line of Credit and Term Loan | |||||
Debt Instrument | |||||
Debt instrument, covenant debt to assets (as a percent) | 60.00% | 60.00% | |||
Debt instrument, covenant secured debt to assets (as a percent) | 30.00% | 30.00% | |||
Debt instrument, covenant unsecured debt to unencumbered assets (as a percent) | 60.00% | 60.00% | |||
Debt instrument, covenant minimum fixed charge coverage ratio | 1.5 | 1.5 | |||
Debt instrument, covenant net worth | $ 6,500,000,000 | ||||
2015 Term Loan | |||||
Debt Instrument | |||||
Length of debt instrument extension period | 1 year | ||||
Outstanding balance on term loan | $ 237,000,000 | £ 169 | |||
GBP LIBOR | 2015 Term Loan | |||||
Debt Instrument | |||||
Debt instrument, basis spread on variable rate (as a percent) | 1.15% | ||||
Bank Line of Credit | Revolving Credit Facility | |||||
Debt Instrument | |||||
Line of credit facility, maximum borrowing capacity | $ 2,000,000,000 | ||||
Number of extensions | renewal_option | 2 | 2 | |||
Length of debt instrument extension period | 6 months | ||||
Debt instrument, facility fee (as a percent) | 0.20% | ||||
Line of credit facility additional aggregate amount, maximum | $ 750,000,000 | ||||
Bank line of credit | 1,100,000,000 | ||||
Debt denominated in foreign currency outstanding | $ 147,000,000 | £ 105 | |||
Weighted-average interest rate (as a percent) | 2.99% | 2.99% | |||
Bank Line of Credit | Revolving Credit Facility | Subsequent Event | |||||
Debt Instrument | |||||
Repayment under bank line of credit | $ 290,000,000 | ||||
Bank Line of Credit | Revolving Credit Facility | LIBOR | |||||
Debt Instrument | |||||
Debt instrument, basis spread on variable rate (as a percent) | 1.00% |
Debt - Senior Unsecured Notes (
Debt - Senior Unsecured Notes (Details) - USD ($) | Jul. 27, 2017 | May 01, 2017 | Mar. 31, 2018 | Dec. 31, 2017 |
Debt Instrument | ||||
Principal balance on debt | $ 7,917,236,000 | |||
Senior unsecured notes | 6,398,976,000 | $ 6,396,451,000 | ||
Unsecured Debt | ||||
Debt Instrument | ||||
Principal balance on debt | 6,450,000,000 | |||
Senior unsecured notes | $ 0 | $ 0 | ||
Unsecured Note 5.625% | ||||
Debt Instrument | ||||
Repayment of senior unsecured notes | $ 250,000,000 | |||
Percentage of stated interest rate | 5.625% | |||
Unsecured Note 5.375% | ||||
Debt Instrument | ||||
Repayment of senior unsecured notes | $ 500,000,000 | |||
Percentage of stated interest rate | 5.375% |
Debt - Mortgage Debt (Details)
Debt - Mortgage Debt (Details) $ in Thousands, £ in Millions | 1 Months Ended | 3 Months Ended | ||
Mar. 31, 2017USD ($) | Mar. 31, 2018USD ($)facility | Mar. 31, 2018GBP (£)facility | Dec. 31, 2017USD ($) | |
Debt Instrument | ||||
Term loan | $ 236,878 | $ 228,288 | ||
Total debt before discount, net | 7,917,236 | |||
(Discounts), premiums and debt costs, net | (45,501) | |||
Debt instruments, carrying amount | 7,871,735 | |||
Other debt | 93,856 | $ 94,165 | ||
Debt maturing in 2018 | ||||
Debt Instrument | ||||
2018 (nine months) | 2,649 | |||
Debt maturing in 2019 | ||||
Debt Instrument | ||||
2,019 | 690,875 | |||
Debt maturing in 2020 | ||||
Debt Instrument | ||||
2,020 | 803,758 | |||
Debt maturing in 2021 | ||||
Debt Instrument | ||||
2,021 | 1,803,474 | |||
Debt maturing in 2022 | ||||
Debt Instrument | ||||
2,022 | 902,861 | |||
Thereafter | ||||
Debt Instrument | ||||
Thereafter | 3,713,619 | |||
2015 Term Loan | ||||
Debt Instrument | ||||
Term loan | 237,000 | £ 169 | ||
Bank Line of Credit | ||||
Debt Instrument | ||||
Total debt before discount, net | 1,092,357 | |||
(Discounts), premiums and debt costs, net | 0 | |||
Debt instruments, carrying amount | 1,092,357 | |||
Bank Line of Credit | Debt maturing in 2018 | ||||
Debt Instrument | ||||
2018 (nine months) | 0 | |||
Bank Line of Credit | Debt maturing in 2019 | ||||
Debt Instrument | ||||
2,019 | 0 | |||
Bank Line of Credit | Debt maturing in 2020 | ||||
Debt Instrument | ||||
2,020 | 0 | |||
Bank Line of Credit | Debt maturing in 2021 | ||||
Debt Instrument | ||||
2,021 | 1,092,357 | |||
Bank Line of Credit | Debt maturing in 2022 | ||||
Debt Instrument | ||||
2,022 | 0 | |||
Bank Line of Credit | Thereafter | ||||
Debt Instrument | ||||
Thereafter | 0 | |||
Term loans | ||||
Debt Instrument | ||||
Total debt before discount, net | 237,175 | |||
(Discounts), premiums and debt costs, net | (297) | |||
Debt instruments, carrying amount | 236,878 | |||
Term loans | Debt maturing in 2018 | ||||
Debt Instrument | ||||
2018 (nine months) | 0 | |||
Term loans | Debt maturing in 2019 | ||||
Debt Instrument | ||||
2,019 | 237,175 | |||
Term loans | Debt maturing in 2020 | ||||
Debt Instrument | ||||
2,020 | 0 | |||
Term loans | Debt maturing in 2021 | ||||
Debt Instrument | ||||
2,021 | 0 | |||
Term loans | Debt maturing in 2022 | ||||
Debt Instrument | ||||
2,022 | 0 | |||
Term loans | Thereafter | ||||
Debt Instrument | ||||
Thereafter | 0 | |||
Unsecured Debt | ||||
Debt Instrument | ||||
Total debt before discount, net | 6,450,000 | |||
(Discounts), premiums and debt costs, net | (51,024) | |||
Debt instruments, carrying amount | $ 6,398,976 | |||
Weighted-average interest rate (as a percent) | 4.20% | 4.20% | ||
Weighted-average maturity | 6 years | |||
Unsecured Debt | Minimum | ||||
Debt Instrument | ||||
Percentage of stated interest rate | 2.79% | 2.79% | ||
Unsecured Debt | Maximum | ||||
Debt Instrument | ||||
Percentage of stated interest rate | 6.88% | 6.88% | ||
Unsecured Debt | Debt maturing in 2018 | ||||
Debt Instrument | ||||
2018 (nine months) | $ 0 | |||
Unsecured Debt | Debt maturing in 2019 | ||||
Debt Instrument | ||||
2,019 | 450,000 | |||
Unsecured Debt | Debt maturing in 2020 | ||||
Debt Instrument | ||||
2,020 | 800,000 | |||
Unsecured Debt | Debt maturing in 2021 | ||||
Debt Instrument | ||||
2,021 | 700,000 | |||
Unsecured Debt | Debt maturing in 2022 | ||||
Debt Instrument | ||||
2,022 | 900,000 | |||
Unsecured Debt | Thereafter | ||||
Debt Instrument | ||||
Thereafter | $ 3,600,000 | |||
Mortgage Debt | ||||
Debt Instrument | ||||
Number of healthcare facilities used to secure debt | facility | 16 | 16 | ||
Debt instrument, collateral, healthcare facilities carrying value | $ 296,000 | |||
Repayments of debt | $ 472,000 | |||
Total debt before discount, net | 137,704 | |||
(Discounts), premiums and debt costs, net | 5,820 | |||
Debt instruments, carrying amount | $ 143,524 | |||
Weighted-average interest rate (as a percent) | 4.18% | 4.18% | ||
Weighted-average maturity | 20 years | |||
Mortgage Debt | Minimum | ||||
Debt Instrument | ||||
Percentage of stated interest rate | 1.95% | 1.95% | ||
Mortgage Debt | Maximum | ||||
Debt Instrument | ||||
Percentage of stated interest rate | 5.91% | 5.91% | ||
Mortgage Debt | Debt maturing in 2018 | ||||
Debt Instrument | ||||
2018 (nine months) | $ 2,649 | |||
Mortgage Debt | Debt maturing in 2019 | ||||
Debt Instrument | ||||
2,019 | 3,700 | |||
Mortgage Debt | Debt maturing in 2020 | ||||
Debt Instrument | ||||
2,020 | 3,758 | |||
Mortgage Debt | Debt maturing in 2021 | ||||
Debt Instrument | ||||
2,021 | 11,117 | |||
Mortgage Debt | Debt maturing in 2022 | ||||
Debt Instrument | ||||
2,022 | 2,861 | |||
Mortgage Debt | Thereafter | ||||
Debt Instrument | ||||
Thereafter | $ 113,619 |
Equity (Details)
Equity (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Accumulated Other Comprehensive Loss | ||
Cumulative foreign currency translation adjustment | $ 697 | $ (6,955) |
Unrealized gains (losses) on cash flow hedges, net | (18,989) | (13,950) |
Supplemental Executive Retirement plan minimum liability and other | (3,015) | (3,119) |
Total other comprehensive income (loss) | $ (21,307) | $ (24,024) |
Segment Disclosures - Summary I
Segment Disclosures - Summary Information for the Reportable Segments (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | |||
Jan. 31, 2018USD ($) | Mar. 31, 2017USD ($) | Jan. 31, 2017USD ($) | Mar. 31, 2018USD ($)facility | Mar. 31, 2017USD ($)facility | |
Segment Disclosure | |||||
Number of SH NNN facilities transitioned to RIDEA structure | facility | 0 | ||||
Segment reporting information, revenues | |||||
Rental revenues | $ 472,832 | $ 473,837 | |||
Operating expenses | (172,552) | (159,081) | |||
Segment NOI | 300,280 | 314,756 | |||
Adjustments to NOI | (9,686) | (4,427) | |||
Adjusted NOI | 290,594 | 310,329 | |||
Addback adjustments | 9,686 | 4,427 | |||
Interest income | 6,365 | 18,331 | |||
Interest expense | (75,102) | (86,718) | |||
Depreciation and amortization | (143,250) | (136,554) | |||
General and administrative | (29,175) | (22,478) | |||
Transaction costs | (2,195) | (1,057) | |||
Gain (loss) on sales of real estate, net | 20,815 | 317,258 | |||
Other income (expense), net | (40,407) | 51,208 | |||
Income tax benefit (expense) | 5,336 | 6,162 | |||
Equity income (loss) from unconsolidated JVs | 570 | 3,269 | |||
Net income (loss) | 43,237 | 464,177 | |||
Corporate and other assets | |||||
Segment reporting information, revenues | |||||
Rental revenues | 0 | 0 | |||
Operating expenses | 0 | 0 | |||
Segment NOI | 0 | 0 | |||
Adjustments to NOI | 0 | 0 | |||
Adjusted NOI | 0 | 0 | |||
Addback adjustments | 0 | 0 | |||
Interest income | 0 | 0 | |||
Interest expense | (72,583) | (79,265) | |||
Depreciation and amortization | 0 | 0 | |||
General and administrative | (29,175) | (22,478) | |||
Transaction costs | (2,195) | (1,057) | |||
Gain (loss) on sales of real estate, net | 0 | 0 | |||
Other income (expense), net | 160 | 313 | |||
Income tax benefit (expense) | 5,336 | 6,162 | |||
Equity income (loss) from unconsolidated JVs | 0 | 0 | |||
Net income (loss) | (98,457) | $ (96,325) | |||
Senior housing triple-net | |||||
Segment Disclosure | |||||
Number of SH NNN facilities transitioned to RIDEA structure | facility | 1 | ||||
Segment reporting information, revenues | |||||
Gain (loss) on sales of real estate, net | $ 170,000 | ||||
Senior housing triple-net | Operating segment | |||||
Segment reporting information, revenues | |||||
Rental revenues | 74,289 | $ 100,034 | |||
Operating expenses | (1,045) | (1,111) | |||
Segment NOI | 73,244 | 98,923 | |||
Adjustments to NOI | (1,865) | (1,839) | |||
Adjusted NOI | 71,379 | 97,084 | |||
Addback adjustments | 1,865 | 1,839 | |||
Interest income | 0 | 0 | |||
Interest expense | (600) | (627) | |||
Depreciation and amortization | (21,906) | (26,411) | |||
General and administrative | 0 | 0 | |||
Transaction costs | 0 | 0 | |||
Gain (loss) on sales of real estate, net | 0 | 268,464 | |||
Other income (expense), net | 0 | 0 | |||
Income tax benefit (expense) | 0 | 0 | |||
Equity income (loss) from unconsolidated JVs | 0 | 0 | |||
Net income (loss) | 50,738 | 340,349 | |||
SHOP | |||||
Segment reporting information, revenues | |||||
Gain (loss) on sales of real estate, net | $ 21,000 | ||||
SHOP | Operating segment | |||||
Segment reporting information, revenues | |||||
Rental revenues | 144,670 | 140,228 | |||
Operating expenses | (101,746) | (94,539) | |||
Segment NOI | 42,924 | 45,689 | |||
Adjustments to NOI | (1,607) | (310) | |||
Adjusted NOI | 41,317 | 45,379 | |||
Addback adjustments | 1,607 | 310 | |||
Interest income | 0 | 0 | |||
Interest expense | (988) | (4,596) | |||
Depreciation and amortization | (27,628) | (26,358) | |||
General and administrative | 0 | 0 | |||
Transaction costs | 0 | 0 | |||
Gain (loss) on sales of real estate, net | 20,815 | 366 | |||
Other income (expense), net | 0 | 0 | |||
Income tax benefit (expense) | 0 | 0 | |||
Equity income (loss) from unconsolidated JVs | 0 | 0 | |||
Net income (loss) | 35,123 | 15,101 | |||
Life science | |||||
Segment reporting information, revenues | |||||
Gain (loss) on sales of real estate, net | $ 45,000 | ||||
Life science | Operating segment | |||||
Segment reporting information, revenues | |||||
Rental revenues | 99,622 | 85,321 | |||
Operating expenses | (21,809) | (17,319) | |||
Segment NOI | 77,813 | 68,002 | |||
Adjustments to NOI | (3,751) | (305) | |||
Adjusted NOI | 74,062 | 67,697 | |||
Addback adjustments | 3,751 | 305 | |||
Interest income | 0 | 0 | |||
Interest expense | (83) | (104) | |||
Depreciation and amortization | (36,080) | (33,791) | |||
General and administrative | 0 | 0 | |||
Transaction costs | 0 | 0 | |||
Gain (loss) on sales of real estate, net | 0 | 44,633 | |||
Other income (expense), net | 0 | 0 | |||
Income tax benefit (expense) | 0 | 0 | |||
Equity income (loss) from unconsolidated JVs | 0 | 0 | |||
Net income (loss) | 41,650 | 78,740 | |||
Medical office | Operating segment | |||||
Segment reporting information, revenues | |||||
Rental revenues | 123,935 | 118,371 | |||
Operating expenses | (46,696) | (44,864) | |||
Segment NOI | 77,239 | 73,507 | |||
Adjustments to NOI | (1,071) | (961) | |||
Adjusted NOI | 76,168 | 72,546 | |||
Addback adjustments | 1,071 | 961 | |||
Interest income | 0 | 0 | |||
Interest expense | (120) | (129) | |||
Depreciation and amortization | (45,519) | (42,729) | |||
General and administrative | 0 | 0 | |||
Transaction costs | 0 | 0 | |||
Gain (loss) on sales of real estate, net | 0 | 0 | |||
Other income (expense), net | 0 | 0 | |||
Income tax benefit (expense) | 0 | 0 | |||
Equity income (loss) from unconsolidated JVs | 0 | 0 | |||
Net income (loss) | 31,600 | 30,649 | |||
Other non-reportable segments | Operating segment | |||||
Segment reporting information, revenues | |||||
Rental revenues | 30,316 | 29,883 | |||
Operating expenses | (1,256) | (1,248) | |||
Segment NOI | 29,060 | 28,635 | |||
Adjustments to NOI | (1,392) | (1,012) | |||
Adjusted NOI | 27,668 | 27,623 | |||
Addback adjustments | 1,392 | 1,012 | |||
Interest income | 6,365 | 18,331 | |||
Interest expense | (728) | (1,997) | |||
Depreciation and amortization | (12,117) | (7,265) | |||
General and administrative | 0 | 0 | |||
Transaction costs | 0 | 0 | |||
Gain (loss) on sales of real estate, net | 0 | 3,795 | |||
Other income (expense), net | (40,567) | 50,895 | |||
Income tax benefit (expense) | 0 | 0 | |||
Equity income (loss) from unconsolidated JVs | 570 | 3,269 | |||
Net income (loss) | $ (17,417) | $ 95,663 |
Segment Disclosures - Revenues
Segment Disclosures - Revenues and Assets by Segment (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Segment Disclosure | ||
Total revenues | $ 479,197 | $ 492,168 |
Operating segment | ||
Segment Disclosure | ||
Total revenues | 479,197 | 492,168 |
Operating segment | Senior housing triple-net | ||
Segment Disclosure | ||
Total revenues | 74,289 | 100,034 |
Operating segment | SHOP | ||
Segment Disclosure | ||
Total revenues | 144,670 | 140,228 |
Operating segment | Life science | ||
Segment Disclosure | ||
Total revenues | 99,622 | 85,321 |
Operating segment | Medical office | ||
Segment Disclosure | ||
Total revenues | 123,935 | 118,371 |
Operating segment | Other non-reportable segments | ||
Segment Disclosure | ||
Total revenues | $ 36,681 | $ 48,214 |
Earnings Per Common Share (Deta
Earnings Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Numerator | ||
Net income (loss) from continuing operations | $ 43,237 | $ 464,177 |
Noncontrolling interests' share in earnings | (3,005) | (3,032) |
Net income (loss) attributable to HCP, Inc. | 40,232 | 461,145 |
Less: Participating securities' share in earnings | (391) | (770) |
Net income (loss) applicable to common shares | 39,841 | 460,375 |
Numerator - Dilutive | ||
Net income (loss) applicable to common shares | 39,841 | 460,375 |
Add: distributions on dilutive convertible units and other | 0 | 2,803 |
Dilutive net income (loss) available to common shares | $ 39,841 | $ 463,178 |
Denominator | ||
Basic weighted average common shares | 469,557 | 468,299 |
Diluted weighted average common shares | 469,695 | 475,173 |
Earnings per common share: | ||
Earnings per common share, basic (in dollars per share) | $ 0.08 | $ 0.98 |
Earnings per common share, diluted (in dollars per share) | $ 0.08 | $ 0.97 |
Equity awards | ||
Denominator | ||
Dilutive potential common shares | 138 | 229 |
Down REIT | ||
Denominator | ||
Dilutive potential common shares | 0 | 6,645 |
Earnings per common share: | ||
Shares of anti-dilutive securities excluded from earnings per share calculation | 7,000 | |
DownREIT LLCs, non-managing member units outstanding | 4,000 |
Supplemental Cash Flow Inform66
Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Supplemental cash flow information: | ||
Interest paid, net of capitalized interest | $ 92,701 | $ 108,232 |
Income taxes paid | 340 | 1,105 |
Capitalized interest | 3,578 | 3,090 |
Supplemental schedule of non-cash investing and financing activities: | ||
Accrued construction costs | 62,160 | 51,498 |
Derecognition of U.K. Bridge Loan receivable | 147,474 | 0 |
Consolidation of net assets related to U.K. Bridge Loan | 106,457 | 0 |
Deconsolidation of noncontrolling interest in connection with RIDEA II transaction | 0 | 58,061 |
Vesting of restricted stock units and conversion of non-managing member units into common stock | $ 258 | $ 1,841 |
Supplemental Cash Flow Inform67
Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 | Mar. 31, 2017 |
Supplementary Insurance Information [Abstract] | |||
Cash and cash equivalents | $ 86,021 | $ 55,306 | $ 764,114 |
Restricted cash | 31,947 | $ 26,897 | 60,806 |
Cash, cash equivalents and restricted cash | $ 117,968 | $ 824,920 |
Variable Interest Entities - Na
Variable Interest Entities - Narrative (Details) $ in Thousands, £ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||
Mar. 31, 2017property | Mar. 31, 2018USD ($)propertyfacilityjoint_venturetenantloan | Mar. 31, 2018GBP (£)facilityjoint_venture | Mar. 31, 2017USD ($) | Dec. 31, 2017USD ($)property | Dec. 31, 2016USD ($)property | Mar. 31, 2018GBP (£)propertyjoint_venturetenantloan | Dec. 31, 2016GBP (£)property | |
Variable Interest Entity [Line Items] | ||||||||
Mezzanine | $ | $ 22,105 | $ 269,299 | ||||||
Loans receivable, net | $ | 47,012 | $ 313,326 | ||||||
Loss from initial consolidation of VIE | $ | $ 41,017 | $ 0 | ||||||
Senior housing triple-net | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Number of properties sold | property | 64 | |||||||
Unconsolidated Variable Interest Entities | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Number of unconsolidated joint ventures | joint_venture | 5 | 5 | ||||||
Number of VIE borrowers with marketable debt securities | joint_venture | 1 | 1 | ||||||
Number of loans to VIE borrowers | loan | 1 | 1 | ||||||
CCRC OpCo | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Ownership percentage (as a percent) | 49.00% | 49.00% | ||||||
Vintage Park Development JV | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Ownership percentage (as a percent) | 85.00% | 85.00% | ||||||
Waldwick | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Ownership percentage (as a percent) | 85.00% | 85.00% | ||||||
VIE tenants-operating leases | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Number of properties leased | property | 48 | 48 | ||||||
Number of VIE tenants | tenant | 7 | 7 | ||||||
Loan - Seller Financing | Senior housing triple-net | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Mezzanine | $ | $ 10,000 | |||||||
Number of properties sold | facility | 7 | 7 | ||||||
Term of facility | 5 years | 5 years | ||||||
HCP Ventures V | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Ownership percentage (as a percent) | 51.00% | 51.00% | ||||||
Vintage Park JV | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Ownership percentage (as a percent) | 90.00% | 90.00% | ||||||
Watertown JV | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Ownership percentage (as a percent) | 95.00% | 95.00% | ||||||
Hayden JV | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Ownership percentage (as a percent) | 99.00% | 99.00% | ||||||
Consolidated lessees VIE | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Number of properties leased | property | 21 | 21 | ||||||
DownREIT Partnerships | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Number of controlling ownership interest entities as a managing member | joint_venture | 5 | 5 | ||||||
MMCG | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Loss from initial consolidation of VIE | $ 41,000 | £ 29 | ||||||
Tax benefit of initial consolidation of variable interest entity | 3,000 | 2 | ||||||
Carrying amount of liabilities in VIE | 13,000 | £ 9 | ||||||
MMCG | Property, plant and equipment | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Carrying amount of assets in VIE | 114,000 | 81 | ||||||
MMCG | Intangible assets | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Carrying amount of assets in VIE | 5,000 | £ 4 | ||||||
MMCG | Bridge Loan | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Loans receivable, net | $ 131,000 | £ 105 | ||||||
Number of properties in a purchase option | property | 7 | 7 | ||||||
Period of call-option retained | 3 years | |||||||
Loss from initial consolidation of VIE | 41,000 | £ 29 | ||||||
Exchange Accommodation Titleholder | ||||||||
Variable Interest Entity [Line Items] | ||||||||
Carrying amount of assets in VIE | $ | $ 153,000 | |||||||
Number of properties acquired | property | 11 |
Variable Interest Entities - Sc
Variable Interest Entities - Schedule of Variable Interest Entities (Details) $ in Thousands | Mar. 31, 2018USD ($) |
VIE tenants-DFLs | |
Variable Interest Entity [Line Items] | |
Maximum Loss Exposure and Carrying Amount | $ 600,822 |
VIE tenants-operating leases | |
Variable Interest Entity [Line Items] | |
Maximum Loss Exposure and Carrying Amount | 5,983 |
CCRC OpCo | |
Variable Interest Entity [Line Items] | |
Maximum Loss Exposure and Carrying Amount | 190,662 |
RIDEA II | |
Variable Interest Entity [Line Items] | |
Maximum Loss Exposure and Carrying Amount | 309,882 |
Unconsolidated Development JVs | |
Variable Interest Entity [Line Items] | |
Maximum Loss Exposure and Carrying Amount | 13,070 |
Loan - Seller Financing | |
Variable Interest Entity [Line Items] | |
Maximum Loss Exposure and Carrying Amount | 10,000 |
CMBS and LLC investment | |
Variable Interest Entity [Line Items] | |
Maximum Loss Exposure and Carrying Amount | $ 33,874 |
Variable Interest Entities - Co
Variable Interest Entities - Consolidated Assets and Liabilities of VIEs (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 | Mar. 31, 2017 |
ASSETS | |||
Buildings and improvements | $ 11,532,338 | $ 11,239,732 | |
Development costs and construction in progress | 344,948 | 447,976 | |
Land | 1,808,210 | 1,785,865 | |
Accumulated depreciation and amortization | (2,826,325) | (2,741,695) | |
Net real estate | 10,859,171 | 10,731,878 | |
Investments in and advances to unconsolidated joint ventures | 863,775 | 800,840 | |
Accounts receivable, net | 51,468 | 40,733 | |
Cash and cash equivalents | 86,021 | 55,306 | $ 764,114 |
Restricted cash | 31,947 | 26,897 | $ 60,806 |
Intangible assets, net | 395,298 | 410,082 | |
Other assets, net | 583,261 | 578,033 | |
Total assets | 14,067,571 | 14,088,461 | |
LIABILITIES AND EQUITY | |||
Mortgage debt | 143,524 | 144,486 | |
Intangible liabilities, net | 52,576 | 52,579 | |
Accounts payable and accrued liabilities | 8,564 | 14,031 | |
Deferred revenue | 167,975 | 144,709 | |
Total liabilities | 8,586,648 | 8,493,523 | |
VIEs | |||
ASSETS | |||
Buildings and improvements | 1,744,402 | 2,436,414 | |
Development costs and construction in progress | 16,226 | 32,285 | |
Land | 170,889 | 227,162 | |
Accumulated depreciation and amortization | (345,331) | (542,091) | |
Net real estate | 1,586,186 | 2,153,770 | |
Investments in and advances to unconsolidated joint ventures | 2,148 | 2,231 | |
Accounts receivable, net | 7,287 | 10,242 | |
Cash and cash equivalents | 12,077 | 15,861 | |
Restricted cash | 2,595 | 2,619 | |
Intangible assets, net | 111,149 | 125,475 | |
Other assets, net | 35,788 | 33,749 | |
Total assets | 1,757,230 | 2,343,947 | |
LIABILITIES AND EQUITY | |||
Mortgage debt | 44,882 | 45,016 | |
Intangible liabilities, net | 12,509 | 10,672 | |
Accounts payable and accrued liabilities | 223,708 | 269,280 | |
Deferred revenue | 15,275 | 14,432 | |
Total liabilities | $ 296,374 | $ 339,400 |
Concentration of Credit Risk -
Concentration of Credit Risk - Schedule of Concentration Risk (Details) - property | 1 Months Ended | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2018 | Mar. 31, 2017 | Dec. 31, 2017 | |
Total Assets | Brookdale | ||||
Concentration Risk [Line Items] | ||||
Concentration risk (as a percent) | 10.00% | 10.00% | ||
Revenue | Brookdale | ||||
Concentration Risk [Line Items] | ||||
Concentration risk (as a percent) | 7.00% | 12.00% | ||
Senior housing triple-net | ||||
Concentration Risk [Line Items] | ||||
Number of properties disposed | 64 | |||
Senior housing triple-net | Total Assets | Brookdale | ||||
Concentration Risk [Line Items] | ||||
Concentration risk (as a percent) | 39.00% | 39.00% | ||
Senior housing triple-net | Revenue | Brookdale | ||||
Concentration Risk [Line Items] | ||||
Concentration risk (as a percent) | 43.00% | 60.00% |
Concentration of Credit Risk 72
Concentration of Credit Risk - Narrative (Details) | 3 Months Ended | 12 Months Ended | |
Jun. 30, 2018 | Mar. 31, 2018facilityrenewal | Dec. 31, 2017 | |
Brookdale | Minimum | |||
Concentration Risk [Line Items] | |||
Percentage of EDITDAR payable as base management fee | 4.50% | ||
Brookdale | Maximum | |||
Concentration Risk [Line Items] | |||
Percentage of EDITDAR payable as base management fee | 5.00% | ||
SHOP | Management and Accounting Services | Brookdale | |||
Concentration Risk [Line Items] | |||
Number of facilities | facility | 68 | ||
Number of facilities owned by unconsolidated joint venture | facility | 62 | ||
Management and Accounting Services | SHOP | Brookdale | |||
Concentration Risk [Line Items] | |||
Management agreement renewal term (in years) | 5 years | ||
Management and Accounting Services | SHOP | Brookdale | Minimum | |||
Concentration Risk [Line Items] | |||
Management agreement term (in years) | 10 years | ||
Number of renewals on management agreement | renewal | 3 | ||
Management and Accounting Services | SHOP | Brookdale | Maximum | |||
Concentration Risk [Line Items] | |||
Management agreement term (in years) | 15 years | ||
Number of renewals on management agreement | renewal | 4 | ||
Total Assets | SHOP | Brookdale | |||
Concentration Risk [Line Items] | |||
Concentration risk (as a percent) | 12.00% | 13.00% | |
Brookdale | Total Assets | |||
Concentration Risk [Line Items] | |||
Concentration risk (as a percent) | 10.00% | 10.00% | |
RIDEA II | Forecast | HCP/CPA/Brookdale JV | |||
Concentration Risk [Line Items] | |||
Investment ownership percentage | 40.00% |
Fair Value Measurements - Summa
Fair Value Measurements - Summary of the Carrying Amounts and Fair Values of the Financial Instruments (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Summary of financial instruments | ||
Bank line of credit | $ 1,092,357 | $ 1,017,076 |
Senior unsecured notes | 6,398,976 | 6,396,451 |
Mortgage debt | 143,524 | 144,486 |
Other debt | 93,856 | 94,165 |
Carrying Value | ||
Summary of financial instruments | ||
Loans receivable, net | 47,012 | 313,326 |
Marketable debt securities | 18,814 | 18,690 |
Bank line of credit | 1,092,357 | 1,017,076 |
Term loan | 236,878 | 228,288 |
Senior unsecured notes | 6,398,976 | 6,396,451 |
Mortgage debt | 143,524 | 144,486 |
Other debt | 93,856 | 94,165 |
Carrying Value | Interest-rate swap contracts | ||
Summary of financial instruments | ||
Derivative liabilities | 1,931 | 2,483 |
Carrying Value | Currency swap | ||
Summary of financial instruments | ||
Derivative liabilities | 16,684 | 10,968 |
Fair Value | Level 1 | ||
Summary of financial instruments | ||
Senior unsecured notes | 6,577,155 | 6,737,825 |
Fair Value | Level 2 | ||
Summary of financial instruments | ||
Loans receivable, net | 47,075 | 313,242 |
Marketable debt securities | 18,814 | 18,690 |
Bank line of credit | 1,092,357 | 1,017,076 |
Term loan | 236,878 | 228,288 |
Mortgage debt | 137,704 | 125,984 |
Other debt | 93,856 | 94,165 |
Fair Value | Interest-rate swap contracts | Level 2 | ||
Summary of financial instruments | ||
Derivative liabilities | 1,931 | 2,483 |
Fair Value | Currency swap | Level 2 | ||
Summary of financial instruments | ||
Derivative liabilities | $ 16,684 | $ 10,968 |
Derivative Financial Instrume74
Derivative Financial Instruments - Schedule of Derivative Instruments (Details) - Mar. 31, 2018 | USD ($)derivative$ / £ | GBP (£)derivative$ / £ |
Cash Flow | Interest-rate swap contracts | ||
Derivative [Line Items] | ||
Notional | $ 43,000,000 | |
Fixed Rate/Buy Amount (as a percent) | 3.82% | 3.82% |
Fair value of interest rate hedge, liabilities | $ (1,931,000) | |
Number of interest-rate contracts held | derivative | 3 | 3 |
Net Investment | Cross currency swap | ||
Derivative [Line Items] | ||
Notional | £ | £ 105,000,000 | |
Fair value of interest rate hedge, liabilities | $ (16,684,000) | |
Foreign currency exchange rate | $ / £ | 1.251 | 1.251 |
Long | Net Investment | Cross currency swap | ||
Derivative [Line Items] | ||
Notional | £ | £ 105,000,000 | |
Fixed Rate/Buy Amount (as a percent) | 2.58% | 2.58% |
Short | Net Investment | Cross currency swap | ||
Derivative [Line Items] | ||
Notional | $ 131,000,000 | |
Fixed Rate/Buy Amount (as a percent) | 3.75% | 3.75% |
Derivative Financial Instrume75
Derivative Financial Instruments - Narrative (Details) - 3 months ended Mar. 31, 2018 $ in Millions | USD ($) | GBP (£) |
Net Investment | Facility and 2015 Term Loan | ||
Derivative [Line Items] | ||
Borrowings designated as hedge of net investment | £ | £ 150,000,000 | |
Interest-rate swap contracts | Maximum | ||
Derivative [Line Items] | ||
Estimate change in fair value of derivative for assumption of one percentage point change in the interest rate | $ | $ 2 | |
Cross currency swap | Maximum | ||
Derivative [Line Items] | ||
Estimate change in fair value of derivative for assumption of one percentage point change in the interest rate | $ | $ 2 | |
Cross currency swap | Net Investment | ||
Derivative [Line Items] | ||
Notional | £ | £ 105,000,000 |